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Human umbilical cord blood (CB) has become an alternative source of hematopoietic 
stem cells for allogeneic transplantation. However, the varied and small volume in a 
CB collection often results in insufficient cell doses for either speedy reconstitution 
of the patient's blood system or engrafting a patient of large body weight. A delayed 
engraftment may lead to life-threatening infections and bleeding problems. This 
project was aimed to establish the conditions for the ex vivo expansion of enriched 
CB CD34+ cells in the presence of cytokines, in the attempt to increase the dose of 
stem and progenitor cells suitable for transplant. Three studies were conducted: (1) 
comparison of two early-acting cytokines, flt-3 ligand (FL) and stem cell factor 
(SCF) on the expansion of the megakaryocytic lineage; (2) the effects of a novel 
factor, mannose-binding lectin (MBL) on the ex vivo expansion and preservation of 
early stem and progenitor cells; and (3) the culture conditions in terms of duration, 
medium, cytokine combination and autologous plasma for the preclinical ex vivo 
expansion of CB. The read-out system included cell viability, CD34+ and 
CD34+CD38- cells, colony-forming units of the myeloid (CFU-GM), erythroid 
(BFU/CFU-E), megakaryocytic (CFU-MK) and mixed lineages (CFU-GEMM). The 
homing and engraftment of expanded human CD45+ cells and subsets were assessed 
in the bone marrow, spleen and peripheral blood of sub-lethally irradiated non-obese 
xiii 
diabetic (NOD)/severe combined immunodeficient (SCID) mice. 
Our results demonstrated that FL was superior to SCF for the expansion of total 
nucleated cells, CD34+ and CD34+CD38- cells, and megakaryocytic progenitors 
(CFU-MK and CD61+CD41+ cells). We also demonstrated that flt-3 receptor was not 
expressed in megakaryocytic cell lines which suggested that the mechanism of FL on 
the megakaryocytic lineage might be mediated at the stage of hematopoietic 
progenitor cells. 
MBL did not exert any effect on the ex vivo expansion of total nucleated cells or 
progenitor cells of the myeloid and megakaryocytic lineages. However, it increased 
the yields of early progenitor cells (CD34^CD38' cells and CFU-GEMM), 
particularly in prolonged cultures. More significantly, MBL preserved early stem 
cells (CFU-GEMM) in serum-free, cytokine-free medium for up to 35 days of 
culture. 
To establish a clinically applicable protocol for the ex vivo expansion of CB CD34+ 
cells, we demonstrated that both serum-free media QBSF-60 and to a lesser extent 
StemSpan supported the expansion of CD34+ cells. QBSF-60 supported the 
expansion of CD34+ cells up to 64.8-fold, CD34^CD38" cells to 330-fold, CFU-
GEMM to 248-fold, CFU-GM to 407-fold and BFU/CFU-E to 144-fold. The 
expansion of the megakaryocytic lineage was superior in the X-Vivo 10 media 
(CFU-MK up to 684-fold after 12 days of culture). The addition of autologous CB 
plasma promoted CFU-GM and BFU/CFU-E but reduced CD34+CD38- cells and 
CFU-GEMM. The addition of granulocyte-colony stimulating factor (G-CSF) or 
xiv 
interleukin-6 (IL-6) to thrombopoietin (TPO), SCF and FL significantly improved 
the expansion. Expanded cells cultured in QBSF-60 with TPO, SCF and G-CSF 
engrafted and differentiated into multiple lineages of hematopoietic cells in 
NOD/SCID mice. Our data supported the strategy of expanding early and myeloid 
stem and progenitor cells in QBSF-60 and the megakaryocytic lineage in X-Vivo-10 
for 12 days in the presence of TPO, SCF, FL and G-CSF without supplementing with 
FCS or autologous CB plasma. The optimized conditions might be applicable to 
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Section 1.1 Hematopoietic Stem Cells 
1.1.1 Hematopoiesis 
Hematopoiesis is the formation and development of hematopoietic cells (Bell et al. 
1997). During embryonic development, the initial appearance of hematopoietic cells 
was detected at the third week of human gestation in the extraembryonic yolk sac 
blood islands (Bloom et al. 1940, Zon 1995). Recent studies reported the presence of 
CD34+ hematopoietic cells in the aorta-gonad-mesonephros region of 5-week old 
embryos, representing the first intraembryonic site of blood development (Peault 
1996, Tavian et al. 1996, Xu et al. 1998, Marshall et al 1999). By the second month 
of embryonic life, hematopoiesis was transferred to the liver and later supplemented 
by the spleen, thymus and lymph nodes (Bell et al. 1997). The liver remained active 
in blood cell formation until birth but at the fourth month of gestation, the bone 
marrow (BM) started to play an increasing role in the synthesis of stem and 
progenitor cells. Hematopoiesis resided throughout the adult life in the BM. At birth, 
the umbilical cord blood (CB) was rich in early stem and progenitor cells whereas 
levels of these cells were low in the normal adult circulation (Christensen et al. 1986, 
Geissler et al. 1986, Broxmeyer et al 1989). 
1.1.2 Hematopoietic Stem and Progenitor Cells 
Pluripotent hematopoietic stem cells have the capacity for self-renewal and 
differentiation into the complete blood system consisting of erythroid, lymphoid, 
myeloid and megakaryocytic cells (Figure 1.1). These cells were able to reconstitute 
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Figure 1.1 Regulation of Hematopoiesis by Cytokines 
Cytokines regulate blood cell development by mediating proliferation, 
differentiation and maturation of hematopoietic progenitor cells. 
(Reprinted from Bell et al 1997) 
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1997). Progenitor cells, however, were unable to self-renew and irreversibly 
committed to one specific cell lineage. In general, it has been suggested that 
pluripotent stem cells supported long-term engraftment whereas progenitor cells 
enable short-term engraftment after transplantation. 
Hematopoietic stem and progenitor cells have been characterized by the expression 
of various cell surface markers. The CD34 antigen has been established as the 
marker for these cells (Civin et al. 1984, Berenson et al 1988，Sutherland et al. 
1989，DiGiusto et al 1994, Galy et al 1994, Bhatia et al 1997a). There has been no 
single exclusive marker for the identification of pluripotent stem cells. However, the 
subpopulations of CD34+ cells which were lineage marker negative, such as CD38' 
and HLA-DR", were considered to contain the early progenitor cells (Sutherland et 
al. 1989，Verfaillie et al 1990, Terstappen et al. 1991, Verfaillie et al. 1993, Huang 
et al. 1994). Recently, Ziegler et al. (1999) reported that the vascular endothelial 
growth factor receptor 2 or KDR might be a marker for pluripotent stem cells. KDR+ 
cells were about 0.1 — 0.5% of human CD34+ cells. In addition, it has been suggested 
that the early quiescent stem cells might be CD34' (Osawa et al 1996, Goodell et al. 
1997, Bhatia et al 1998, Zanjani et al 1998, Goodell 1999, Sato et al. 1999) and the 
CD34 antigen expression might be up-regulated in response to proliferative signals 
(Goodell 1999). 
For functional assays of hematopoietic progenitors, in vitro assays of colony-forming 
units (CFU), long-term culture-initiating cells (LTC-IC), cobblestone area-forming 
cells (CAPC) and the in vivo non-obese diabetic (NOD)/severe combined 
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immunodeficient (SCID) mouse transplantation model have been used for the 
identification of early stem and progenitor cells of various specific lineages. 
Section 1.2 Stem Cell Transplantation 
1.2.1 Stem Cell Transplantation 
Hematopoietic stem cell transplantation has been proven to provide definitive 
therapy for a variety of high-risk or recurrent hematologic malignancies, marrow 
failure syndromes, selected hereditary immunodeficiency states, metabolic disorders 
and solid tumors. Hematopoietic stem cells could be obtained from related or 
unrelated donors (allogeneic transplant). Alternatively, stem cells might be collected 
from cancer patients (autologous transplant) at remission and these cells could be 
reinfused to them prior to subsequent high-dose chemotherapy/radiotherapy. 
However, the infusion of autologous stem cells might result in the re-introduction of 
contaminating cancer cells (Takvorian et al. 1987). 
1.2.2 Sources of Hematopoietic Stem Cells for Transplantation 
Since the first successful bone marrow transplantation (BMT) was carried out almost 
40 years ago (Thomas et al 1959), BM has been the source of donor stem and 
progenitor cells. The establishment of human leukocyte antigen (HLA) typing 
enabled the selection of major histocompatibility complex (MHC)-compatible 
donor/recipient pairs (Dausset et al. 1970, Bach et al. 1976). The main limitations to 
allogeneic BMT have been the lack of suitable HLA-matched donors and the 
complications of graft-versus-host disease (GVHD) associated with HLA disparities. 
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Peripheral blood stem cells (PBSC) have been used as a source of hematopoietic 
stem and progenitor cells for transplantation since 1990s (Rizzo 1998). The normal 
adult peripheral blood (PB) did not contain significant amount of stem and 
progenitor cells. Upon stimulation by cytokines such as granulocyte-colony 
stimulating factor (G-CSF) (Stahel et al. 1994, Goldman 1995, Klumpp et al. 1995, 
Lane et al. 1995, Li et al 1999) and granulocyte/macrophage-colony stimulating 
factor (GM-CSF) (Corringham et al 1995, Kessinger et al 1995, Lane et al. 1995, 
Passos-Coelho et al 1995), hematopoietic stem and progenitor cells could be 
mobilized into PB from the BM and collected by leukapheresis. The leukapheresis 
procedure was considered to be less morbid than BM harvest by most patients. 
However, the long-term side effects of the mobilizing agents have not been assessed. 
Allogeneic and autologous PBSC transplants have been performed for the treatment 
of malignant and non-malignant diseases (Brugger et al 1995, Alcom et al. 1996, 
Williams et al 1996, Bertonlini et al. 1997a, Holyoake et al. 1997，Reiffers et al. 
1999, McNiece et al. 1999, McNiece et al 2000a, Paquette et al 2000). When PBSC 
transplantation was compared with BMT, rapid neutrophil and platelet recoveries 
were observed in patients received PBSC (Bensinger et al. 1996, Urbano-Ispizua et 
al 1996, Champlin et al 2000). Champlin et al (2000) reported that significantly 
shorter duration of neutrophil (median 14 days) and platelet (18 days) recovery were 
observed in 288 patients receiving PBSC from their HLA-identical siblings when 
compared to the neutrophil (19 days) and platelet (25 days) recovery of 536 BMT 
patients. 
5 
1.2.3 Cord Blood as a Source of Hematopoietic Stem Cells 
The feasibility of using human umbilical CB as a source of transplantable stem and 
progenitor cells for hematopoietic reconstitution was suggested by Broxmeyer et al. 
(1989). The first allogeneic CB transplant was performed successfully in 1988 for 
treating a child with Fanconi's anemia (Gluckman et al. 1989). The donor of this CB 
was his HLA-identical sister. The patient showed full hematopoietic and lymphoid 
reconstitution. As a result, CB banks have been established worldwide to facilitate 
the supply of CB for allogeneic transplants (Rubinstein et al 1993, Rubinstein et al 
1995, Kurtzberg et al 1996, Gluckman et al 1997, Guardiola et al. 2000). At 
present, over 30,000 CB units have been in storage and about 1,500 CB transplants 
have been performed (Kurtzberg et al. 1996, Wagner et al 1995, Gluckman et al. 
1997, Rubinstein et al 1998, Gluckman 2000). 
1.2.3.1 Advantages of Cord Blood Transplant 
Umbilical CB has numerous advantages over BM and PBSC as a source of stem and 
progenitor cells for transplantation. These included the ease and safety of collection, 
lower incidence of infectious agents such as cytomegalovirus (Sirchia et al. 1999). 
CB could be fully tested and HLA-typed prior to cryopreservation and would be 
readily available upon request for transplantation. 
One major advantage of CB transplant has been the reduced incidence and severity 
of acute GVHD (Vormoor et al 1994, Gluckman et al. 1997, Rubinstein et al. 1998, 
Gluckman 2000). Analyzing 138 CB transplants in related children, Gluckman 
(2000) reported that the probabilities of developing acute GVHD > II and chronic 
GVHD were 20% and 6%, respectively. In 291 unrelated children and 108 adult 
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transplants, the acute GVHD > II were 39% and 38%, respectively. These figures 
compared favorably with unrelated BMT of which the acute GVHD > II was 58% 
(Gluckman 2000). In general, CB transplants could tolerate 1 — 2 HLA mistmatches 
between donors and recipients. Therefore, there might be a higher probability of 
finding a suitable CB unit for transplantation when compared to the location of a BM 
donor, in spite of the fact that more than 5 millions BM donors have been included in 
BM donor registries worldwide (Gluckman 2000). 
Hematopoietic stem and progenitor cells in CB were considered as high quality and 
possessed greater proliferative potential than those of BM and PB (Leary et al 1987, 
Carow et al 1991, Verfaillie 1992, Carow et al 1993, Lu et al 1993, Hirao et al 
1994, Vormoor et al 1994, Hao et al 1995, Traycoff al 1995, Mayani et al. 1998, 
Lewis et al 2000). The quantity of LTC-IC in CB was higher when compared to BM 
(Hows et al 1992, Traycoff et al 1995) and PB (Hirao et al. 1994, Lewis et al. 
2000). The number of CFU-GEMM has been shown to be 4-fold higher in CB than 
in BM (Mayani et al 1998). Lu et al. (1993) reported that the frequency of high 
proliferative potential colony-forming cells (HPP-CFC) were 8-fold higher in CB 
than in BM. Moreover, the frequencies of CD34+HLA-DR- and CD34^CD38" cells 
were higher in CB than in BM as reported by Cardoso et al. (1993). 
1.2.3.2 Disadvantages of Cord Blood Transplant 
A major disadvantage of CB transplant has been the once-only collection, varied and 
relatively low cell number in a CB unit. As a result, most transplants especially those 
carried out in early years were performed in patients with small body weights. 
Recently, it has been confirmed that the cell dose in a CB was associated with the 
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outcomes of engraftment. Gluckman (2000) reported that in adult transplants, none 
of the patients who received less than 1 x 10^ nucleated cells/kg body weight 
survived. Patients who received less than 2 x 10^ nucleated cells/kg had a 69% 
probability of reaching > 500/^1 neutrophils and 49% of reaching > 20,000/|LI1 
platelets on day 60. It was thus recommended that the minimum nucleated cell dose 
in a CB unit should be 4 x loVkg of the body weight of the recipient. 
In general, the engraftment kinetics of CB transplant was slower when compared to 
that using other sources of hematopoietic stem and progenitor cells. Gluckman 
(2000) reported the median durations to neutrophil and platelet engraftments in adult 
CB transplants were 32 and 81 days, respectively and were significantly higher than 
those receiving allogeneic BMT. It has been uncertain whether the delays of 
engraftment were results of low cell doses or due to the prematurity of CB stem and 
progenitor cells. The delayed reconstitution of the hematopoietic system in transplant 
patients often resulted in prolonged hospitalization and frequent transfusions of 
blood cells and platelets. In this period, the patients suffered from severe 
myelosuppression or even myeloablation and might develop complications including 
life-threatening infections and bleeding. 
Section 1.3 Ex Vivo Expansion 
The ex vivo expansion of hematopoietic stem and progenitor cells under defined 
conditions in the presence of cytokines has been suggested as an approach for 
overcoming the inadequate number of these cells in a CB unit (Broxmeyer et al. 
1992，Cardoso et al. 1993, Moore et al. 1994, Ruggieri et al. 1994，Traycoff et al. 
1994a, Xiao et al. 1994). The ex vivo expansion of CB cells was first performed by 
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Broxmeyer et al (1992) who cultured mononuclear cells (MNC) from CB and BM in 
Iscove's modified Dulbecco's medium (IMDM) containing 10% fetal calf serum 
(FCS) with cytokine cocktails consisted of stem cell factor (SCF), interleukin-3 (IL-
3)，erythropoietin (EPO), GM-CSF and G-CSF. After 7 days, higher fold increases of 
CFU were obtained in CB cultures than in BM cultures. Since then, numerous studies 
have been undertaken to develop the optimal system for the ex vivo expansion of 
hematopoietic stem and progenitor cells for clinical applications (Moore 1995, 
Emerson 1996, Aglietta et al 1998, Conrad et al. 1998, Shih et al 2000, McNiece 
2001). These included the selection of the appropriate cell populations for expansion, 
the use of new reagents, cytokines, procedures for cell culture and the development 
of approved materials and equipment for clinical expansion. 
Various assays have been used to evaluate the culture outcomes, particularly the 
expansion of primitive hematopoietic progenitor cells. Differential CFU assays were 
employed to assess the expansion of early and committed progenitor cells of the 
mixed (CFU-GEMM), myeloid (CFU-GM), erythroid (BFU/CFU-E) and 
megakaryocytic (CFU-MK) lineages (Alcom et al 1996, Bertolini et al. 1997a, 
Bachier et al. 1999, Kogler et al. 1999). Flow cytometry has also been used to 
distinguish between various progenitor cell subpopulations such as CD34+ cells and 
CD34+CD38-, CD34+CD61+cells (Alcom et al 1996, Bertolini et al 1997a, Kogler 
et al. 1999, Paquette et al 2000). Concurrently, in vivo animal transplantation 
techniques such as the NOD/SCID mouse (Wermann et al. 1996, Bhatia et al 1997b, 
Bhatia et al. 1998, Guenechea et al 1999, Piacibello et al. 1999) and sheep (Yin et 
al. 1997, Almeida-Porada et al 2000) models were developed for the assessment of 
the expansion products. 
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1.3.1 Optimization of Expansion Conditions 
1.3.1.1 CD34+ Cell Selection 
The CD34 antigen is a single-chain 115 kDa cell surface transmembrane 
glycophosphoprotein. At least three distinct CD34 epitopes have been identified 
(Lansdorp et al 1989). In vitro and in vivo data suggested that the human CD34+ cell 
compartment contained primitive multipotential hematopoietic cells for 
transplantation (Srour et al 1991). 
Several studies suggested that CD34+ cell selection was necessary for the optimal 
expansion of hematopoietic stem and progenitor cells (Laver et al. 1995, Zimmerman 
et al. 1995, Charbord et al. 1996, Briddell et al 1997, Cometta et al. 1998, Fietz et 
al 1999). Using selected CB CD34+ cells, Briddell et al. (1997) showed that the fold 
increases of total nucleated cells, CFU-GM and BFU-E were 113, 72.6 and 49.0, 
respectively after 10 days of cultures, whereas the expansions were only 1.4-, 0.8-
and 0.3-fold, respectively in cultures using unselected CB cells. On the other hand, a 
continuously perfused culture system (CPS) has been developed by Aastrom 
Biosciences (Koller et al. 1993) who expanded MNC from CB, BM and PBSC 
without CD34+ cell enrichment (Zandstra et al. 1994, Koller et al 1995, Sandstrom 
et al. 1995, Koller et al 1998). Recently, this system has been applied for clinical 
expansion (Bachier et al 1999, Pecora et al. 2000, Stiffed al 2000). 
A number of methods have been used for the preclinical and clinical enrichment of 
CD34+ cells. In some protocols, CD34+ cell separation was effected by the collection 
of antibody-sensitized cells onto a solid phase such as magnetic beads or columns of 
non-magnetic particles (Chang et al 1985, Ugelstad et al 1986, Holyoake et al. 
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1997，Kogler et al 1999). Commercially developed systems for CD34+ cell selection 
included the Isolex 300 (Nexell; Irvine, CA, USA), Ceprate SC (CellPro Inc., 
Bothell, WA, USA) and Magnetic Activation Cell Sorting (MACS) System (Miltenyi 
Biotec. Inc.; Gladbach, Germany) (Thomas et al. 1994, Korbling et al 1994, 
Miltenyi et al. 1994). For research purposes, high-speed flow cytometry has also 
been employed for CD34+ cell sorting (Uchida et al. 1994). Alternatively, CD34 
negative selection could be performed (StemSep, Stem Cell Technologies, 
Vancouver, BC, Canada) (Bertolini et al. 1997b). 
1.3.1.2 Cytokines 
Hematopoiesis is largely governed by a number of cytokines that promote the 
renewal, proliferation, and differentiation of hematopoietic stem and progenitor cells 
(Figure 1.1). To date, more than 50 cytokines have been shown to play some roles in 
the regulation of hematopoiesis (Al-Homsi et al 2000). Cytokines were secreted by a 
wide variety of cells, including mesenchymal cells such as fibroblasts and 
endothelial cells, monocytes, granulocytes, mast cells, T and B lymphocytes 
(Gualtieri et al 1984, Crosier et al 1992). Non-hematopoietic organs such as the 
liver and kidneys also produced specific cytokines (Crosier et al 1992). 
Cytokines are hormone-like peptides. They exerted their biological function by 
binding to specific receptors on target cells. These receptors have been classified into 
two major families, the hematopoietic receptors and tyrosine kinase receptors 
(Olsson et al 1992, Kishimoto et al. 1994). The hematopoietic receptor family 
included receptors for EPO, GM-CSF, G-CSF, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7 and 
IL-9. The family of tyrosine kinase receptors included receptors for thrombopoietin 
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(TPO), SCF, flt-3 ligand (FL) and colony-stimulating factor-1 (CSF-1). However, 
IL-1 and IL-8 receptors did not belong to any of the two families. 
Some cytokines shared common signal transduction pathway. Cytokines regulated 
hematopoiesis by mechanisms such as modulation of cell cycling, potentiation of 
expression of receptors of other growth factors and regulation of apoptosis (Tanaka 
et al. 1995). A number of cytokines have been demonstrated to promote ex vivo 
expansion of hematopoietic stem and progenitor cells. These included TPO, SCF, 
FL, G-CSF, GM-CSF, IL-ip, IL-3, IL6, IL-11, EPO, macrophage inflammatory 
protein-la (MlP-la), promegapoietin (a chimeric IL-3/TP0 receptor agonist). 
(Naparstek et al 1992, Brugger et al 1995, Alcom et al. 1996, Williams et al. 1996， 
Bertolini et al 1997a, Holyoake et al. 1997, Kogler et al. 1999, Bachier et al. 1999, 
Reiffers et al. 1999, Kratz-Albers et al. 2000, McNiece et al 1999, Pecora et al 
2000, Stiff al. 2000, Paquette et al 2000, McNiece et al 2000a). 
1.3.1.2.1 Thrombopoietin 
TPO has been cloned (Bamett et al. 1994, Kaushansky et al. 1994, Lok et al. 1994, 
Wendling et al. 1994) and considered to be the primary regulator of 
megakaryocytopoiesis (de Sauvage et al. 1994, Kuter et al. 1994). The TPO receptor 
{c-mpl) was first reported in the murine myeloproliferative leukemia virus as the 
transforming oncogene known as v-mpl (Wendling et al. 1986). It was identified on 
megakaryocytes, platelets and primitive hematopoietic progenitors (Vigon et al. 
1992, Young et al. 1996, Ramsfjell et al. 1996). Mice lacking either TPO or its 
receptor were severely thrombocytopenic (Gumey et al. 1994, Alexander et al. 1996, 
de Sauvage et al. 1996). These mice also had significant deficiencies in both early 
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and lineage-committed progenitor cells in the BM (Alexander et al 1996, Carver-
Moore et al 1996，Kimura et al 1998). In addition, administration of TPO to normal 
or myelosuppressive mice resulted in the expansion of all lineages of progenitors in 
their BM and spleen (Han et al 1995, Farese et al. 1996). 
TPO acted on various levels of megakaryocytopoiesis by stimulating the formation 
of megakaryocyte colonies, maturation of immature megakaryocytic progenitors, 
increase in megakaryocyte ploidy and formation of functional platelets (de Sauvage 
et al 1994, Lok et al 1994，Broudy et al 1995, Kaushansky 1995, Cramer et al. 
1997). In ex vivo cultures, TPO alone markedly increased the commitment of stem 
and progenitor cells to the megakaryocytic lineage but did not significantly enhance 
their proliferation (Sieff et al 1989，Briddell et al. 1990, Briddell et al. 1992， 
Quesenberry et al. 1991, van den Oudenijn et al. 1999, Su et al 2001). However, 
TPO enhanced the expansion of megakaryocytic progenitors in the presence of other 
cytokines (Cortes et al 1995, Guerriero et al 1995, Choi et al. 1996, Birkmann et al 
1997’ Borge et al. 1997，Dolzhanskiy et al. 1997, Gehling et al. 1997, Ramsfjell et 
al 1997, Williams et al. 1998, van den Oudenijn et al 1999, Su et al. 2001). TPO 
also acted synergistically with other early-acting cytokines such as SCF and FL in 
supporting the expansion of early progenitor cell populations including CFU-GEMM 
and CD34+CD38"" cells (Ziegler et al. 1994, Ramsfjell et al. 1996, Kobayashi et al. 
1996, Liu et al. 1999). 
A homo log of TPO, the recombinant human pegylated-megakaryocyte growth and 
development factor (MGDF) has been developed for clinical applications to patients 
suffering from thrombocytopenia. The administration of TPO to cancer patients 
receiving chemotherapy resulted in dose-dependent increases of platelet counts and 
13 , 
BM megakaryocytes (Basser et al 1996, O'Malley et al 1996). However, the use of 
MGDF has been challenged due to reports on the development of neutralizing 
antibodies in some patients and normal volunteers (Bolwell et al. 2000, Fields et al. 
2000, Neumann et al 2000). 
1.3.1.2.2 Stem Cell Factor 
SCF has been demonstrated to play a pivotal role in the regulation of early 
hematopoiesis by binding to its receptor c-kit, which was widely expressed in human 
hematopoietic cells (Flanagan et al 1990, Huang et al 1990, Williams et al 1990a, 
Zsebo et al 1990，Andre et al. 1989, Wang et al. 1989，Hu et al. 1994, Morita et al 
1996). Mice with dominant mutations at the SCF and c-kit genes displayed a 
substantial reduction in the number of hematopoietic stem cells with phenotypes such 
as hypoplastic anemia and mast cell deficiency (Broudy 1997). 
As an early-acting cytokine, SCF has been extensively used in the ex vivo expansion 
of human CD34+ cells (Haylock et al 1992, Srour et al. 1992, Henschler et al 1994, 
Mayani et al. 1994, Moore et al 1994, Williams et al 1996). SCF increased all 
lineages ofCFU including CFU-GM, BFU-E, CFU-GEMM and CFU-MK (Brandt et 
al. 1992, Shapiro et al. 1996, Lyman 1998). Ohmizono et al (1997) reported that the 
combination of SCF with TPO, IL-3 and IL-6 or IL-11 enhanced the expansions of 
CB CD34+ cells to CFU-GM, BFU-E and CFU-GEMM after 14 days of cultures. 
The addition of SCF to cultures of BM CD34+ cells increased the expansion of 
CD34+ cells by 0.96 to 2.64-fold (Luens et al. 1998). 
SCF was reported to enhance the effects of G-CSF in the mobilization of PBSC in 
the mouse model (Briddell et al. 1993, Andrews et al 1994a, Yan et al 1994, Yan et 
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al. 1995) and in human clinical trials (Andrews et al 1994b, Glaspy 1996). In the 
latter, SCF, in addition to filgrastim, increased the peak peripheral blood CD34+ cell 
level by 2-3 fold (Glaspy et al 1997, Weaver et al 1998). 
1.3.1.2.3 Flt-3 Ligand 
FL has been shown to possess hematopoietic, lymphopoietic and immunologic 
activities (Lyman 1998). The flt-3 receptors were widely expressed in tissues of 
brain, thymus, skin, kidney, liver and lymph node (Rosnet et al 1991, Meierhoff et 
al. 1995). In the hematopoietic system, flt-3 receptors were identified in stem and 
progenitor cells, granulocytic-monocytic cells, B-lymphocytes and acute leukemic 
cells of lymphoid and myeloid origins (Birg et al 1992, Small et al 1994, Brasel et 
al 1995，Meierhoff et al 1995). Mice deficient in flt-3 had impaired primitive 
hematopoietic progenitor cell functions and reduced B lymphocyte precursors in 
their BM (Mackarehtschian et al 1995). Repeated administration of FL in mice 
increased the hematopoietic progenitor cells in the BM and differentiation of these 
cells into the lymphoid, myeloid and erythroid lineages (Brasel et al. 1996). In 
addition, the in vivo administration of FL induced functional dendritic cells in mice 
(Maraskovsky et al. 1996). 
For the ex vivo expansion of BM or CB CD34+ cells, FL alone had minimal effects 
on the formation of CFU. It produced a small number of CFU-GM, but no BFU-E 
nor CFU-GEMM. However, in combination with other cytokines, such as SCF, IL-3 
and GM-CSF, FL enhanced the expansion of both early and committed progenitor 
cells (CFU-GM, BFU-E, CFU-GEMM and HPP-CFC) (Broxmeyer et a/. 1995). In 
the analysis of the effects of 16 cytokines on CD34^CD38" cells, Petzer et al. (1996) 
reported that FL was the only cytokine to increase the number of LTC-IC from BM 
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CD34+CD38- cells by 30-fold after 10 days of culture. Piacibello et al (1996a) 
suggested that T- and B- lymphocytes could also be expanded in the presence of FL. 
When BM CD34+ cells were expanded with FL, IL-7 and IL-11 for 14 days, the 
percentages of CD2+ and CD 19+ cells reached 33.8% and 3.7%, respectively. In the 
NOD/SCID mouse transplantation model, cells expanded with cytokine cocktails 
containing FL were able to engraft and repopulate in the BM of recipient mice 
(Conneally et al 1997, Dorrell et al 2000, Kusadasi et al 2000, Ueda et al. 2000, 
Yamaguchi et al. 2001). FL increased the engraftment ability of expanded cells in 
NOD/SCID mice by 10 — 13.8 fold (Kusadasi et al 2000). 
FL has been applied to mobilize PBSC in non-human primates together with G-CSF 
and resulted in the significant increase of CFU in their PB. (Papayannopoulou et al 
1997). Administration of FL to patients with metastatic colon cancer led to an 
increase in the number of circulating dentritic cells (Morse et al. 2000). 
1.3.1.2.4 Granulocyte-Colony Stimulating Factor 
G-CSF has been known to promote the myeloid lineage. The G-CSF receptor was 
expressed on hematopoietic cells including pluripotent and myeloid-committed 
progenitors，neutrophils, monocytes and possibly certain lymphocyte subsets 
(Demetri et al 1991). It was also expressed on endothelial cells and G-CSF induced 
their proliferation in vitro (Bocchietto et al. 1993). 
G-CSF acted synergistically with other cytokines on cell proliferation (Metcalf et al 
1995). It increased the neutrophil count and shortened the duration of neutropenia in 
patients after cytotoxic treatments (Demetri et al 1992, Glaspy et al. 1992). G-CSF 
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appeared to be the most effective single agent for the mobilization of neutrophils and 
CD34+ cells for transplantation purposes (Stahel et al. 1994, Goldman et al 1995, 
Klumpp et al. 1995, Lane et al 1995, Li et al 1999). Recently, G-CSF has been 
included in several preclinical and clinical studies on the ex vivo expansion of 
hematopoietic stem and progenitor cells (Briddell et al 1997, Andrews et al 1999, 
Kogler et al. 1999，McNiece et al 1999, Reiffers et al 1999, Kobari et al. 2000, 
Kratz-Albers et al 2000, McNiece et al. 2000a, McNiece et al. 2000b, Paquette et al. 
2000). 
1.3.1.2.5 Interleukin-3 
IL-3 has been considered as a multipotent hematopoietic growth factor produced by 
activated T cells, monocytes/macrophages and stromal cells (Mangi et al. 1999). It 
also promoted early megakaryocytopoiesis (Emerson et al 1988). As a single factor, 
IL-3 supported the proliferation of hematopoietic progenitor cells after they exited 
from the cell cycle Go state (Suda et al 1985, Ogawa 1993). It also synergized with 
TPO (Kobayashi et al 1996, Ku et al 1996), SCF (Tsuji et al 1991, Tsuji et al. 
1992), G-CSF (Ikebuchi et al 1988), IL-6 (Ikebuchi et al 1987) and IL-11 (Musashi 
et al. 1991a, Musashi et al 1991b) in triggering cell divisions of the multipotential 
progenitors in Go. Addition of IL-3 to TPO with IL-1, IL-6, IL-11 and SCF resulted 
in a 1.6-fold increase in the expansion of total nucleated cells (van den Oudenrijn et 
al. 1999). Bryder et al. (2000) demonstrated that IL-3 supported the expansion of 
multipotential progenitors (Lin'Sca-l^Kit^ cells) derived from mouse BM cells in the 
presence of TPO, SCF and FL. 
17 
However, the effects of IL-3 on the maintenance or promotion of early repopulating 
cells during expansion have been controversial (Knobel et al 1994, Yonemura et al 
1995, Shimizu et al. 1998). Some studies reported that IL-3 expanded cells engrafted 
in NOD/SCID mice (Bhatia et al 1997b and Conneally et al. 1997). However, 
Knobel et al. (1994) and Yonemura et al (1995) demonstrated that IL-3 abrogated 
the reconstituting ability of hematopoietic stem cells in vivo. Piacibello et al. (2000) 
demonstrated that IL-3 exhibited an inhibitory effect on the expansion of human 
long-term repopulating hematopoietic stem cells. This observation was in agreement 
with those of Peters et al (1996) and Matsunaga et al (1998), who demonstrated that 
the addition of IL-3 to BM cultures in the presence of IL-6, IL-11 and SCF resulted 
in the impairment of the engrafting capability in NOD/SCID mice. 
Various clinical trials of IL-3 have been performed for the development of new 
therapeutic strategies for cancer patients (Mangi et al 1999). Administration of IL-3 
to patients with relapsed lymphomas, small-cell lung cancer, breast cancer and 
ovarian cancer resulted in the reduction of chemotherapy delays and the faster 
regeneration of granulocytes and platelets (Dercksen et al. 1993, Pedrazzoli et al 
1994). IL-3 has been applied in combination with GM-CSF or G-CSF for PBSC 
mobilization and produced higher cell yields (Dercksen et al. 1995). However, the 
treatment of myelodysplastic syndromes, aplastic anemia and other BM disorders 
with IL-3 has not been effective (Kudoh et al 1996). 
1.3.1.2.6 Interleukin-6 
IL-6 has been reported to promote early hematopoiesis (Ikebuchi et al 1987, 
Jacobsen et al 1994) and megakaryocytopoiesis (Ishibashi et al 1989, Lotem et al. 
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1989，Imai et al 1991). A complex of IL-6 and soluble IL-6 receptor (IL-6/sIL-6R) 
enhanced the expansion of multipotential hematopoietic progenitor cells through 
gpl30 signaling (Ebihara et al 1997, Sui et al 1999). Peters et al (1997) showed 
that IL-6/sIL-6R double transgenic mice had extramedullary expansion of 
hematopoietic progenitor cells and a substantial increase of circulating platelets and 
other lineages of hematopoietic cells. 
IL-6 acted in synergy with other factor on the proliferation of multipotential 
hematopoietic progenitor cells (Piacibello et al. 1999, Rappold et al. 1999，Moore 
2000). The combination of IL-6, FL and TPO supported long-term expansion of total 
nucleated cells, CD34+ cells and CFU-GM (Lazzari et al 2001a). The addition oflL-
6 to cultures of CB CD34+ cells with TPO, SCF and FL improved the engraftment of 
expanded cells in NOD/SCID mice (Kusadasi et al. 2000). For the megakaryocytic 
lineage, IL-6 stimulated the late developmental stages of megakaryocyte maturation 
and polyploidization (Ishibashi et al. 1989, Navarro et al. 1991，Teramura et al. 
1992, Broudy et al 1995). 
Phase I and II trials of IL-6 treatments have been performed in patients with solid 
tumours, aplastic anaemia and B-lymphoproliferative disorders (Weber et al. 1993, 
Banks et al 1995, Schrezenmeier et al 1995, Bouffet et al. 1997, Bracho et al. 2001, 
Haddad et al. 2001). However, high incidence of toxicity was observed in these 
patients, possibly related to the induction of proinflammatory mediators 
(Schrezenmeier et al. 1995, Bracho et al 2001). 
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1.3.1.2.7 Comparison of Flt-3 Ligand and Stem Cell Factor 
FL was structurally related to SCF (Broxmeyer et al 1991，Roth et al. 1992). Lyman 
et al. (1995) demonstrated that while SCF stimulated the expansion of both CD34+ 
and CD34+CD38_ cells, FL only promoted the latter population. The strong 
synergism between FL and SCF suggested that these cytokines were not functionally 
redundant (Lyman et al 1998) and that FL might have a distinct contribution to early 
hematopoietic development. 
FL and SCF also promoted megakaryocytopoiesis. They enhanced the proliferation 
of megakaryocytic progenitors, but had little effect on mature megakaryocytes 
(Briddell et al. 1991，Broudy et al 1995, Piacibello et al 1996a). The mechanism of 
these two early cytokines on the expansion of the megakaryocytic lineage has not 
been clear. Some studies reported that FL promoted better expansion of 
megakaryocytic progenitors than SCF (Bertonlini et al. 1997b, Ohmizono et al 
1997, Shapiro et al 1996). However, others demonstrated that SCF was more 
efficient for the expansion of this lineage (Williams et al. 1998). In addition, FL 
could amplify the megakaryocytic proliferative effects of SCF (Piacibello et al. 
1996b). 
1.3.1.2 Culture Medium 
IMDM has been extensively used in the expansion of hematopoietic stem and 
progenitor cells. FCS, human serum albumin (HSA) or autologous plasma have also 
been included as nutrient supplements. The use of serum-free culture medium has 
been proposed for clinical applications in order to minimize the risk of viral or other 





























































































































































































































































































































































































































































































































































































Capmany et al. (1999) demonstrated that expansion systems using a specific serum-
free medium resulted in more consistent outcomes when compared to serum-
containing cultures. Several commercially available serum-free media have been 
developed and were shown to support more efficient expansion of hematopoietic 
stem and progenitor cells when compared to those using IMDM and FCS 
(Lebkowski et al. 1994, Sandstrom et al. 1996, Collins et al. 1998，Kogler et al. 
1998, Mobest et al 1998, Capmany et al 1999, Lefebvre et al 1999, Mellado-
Damas et al. 1999, Lazzari et al 2001b, van den Oudenrijn et al. 2001) (Table 1.1). 
1.3.2 Mannose-Binding Lectin 
Lectins are glycoproteins which bind to specific carbohydrates in a reversible 
manner. They are ubiquitous in nature and present in microorganisms, plants and 
animals. They have been suggested to play a role in cancer, fertilization, immune 
response and signal transduction. Mannose-binding lectins are those that bind 
specifically to mannose (Meier et al 2000). 
In human, MBL has been isolated in human serum and was involved in innate 
immunity (Saifuddin et al. 2000). In the presence of calcium, MBL could bind to the 
repeating sugar arrays on microbial surfaces, leading to the direct uptake by 
phagocytes. Low serum levels of MBL were observed in some patients with 
suspected immunodeficiencies, unexplained infections and systemic lupus 
erythematosus (Turner 1998). MBL was suggested to be an inhibitor of human 
immunodeficiency virus type-1 and cytomegalovirus replication in vitro (Balzarini et 
al 1991, Balzarini et al. 1992). 
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Plant MBL have been shown to exert some effects on hematopoietic cells. The in 
vivo treatment with MBL extracted from bulbs (Ooi et al. 1998) induced the 
expression of IL-ip, TNF-a and immuno-reactive nitric oxide synthetase in 
splenocytes and macrophages of mice (Ooi et al 2001). Recently, the Flt-3 receptor-
interacting lectin (FRIL) extracted from red kidney beans stimulated the proliferation 
ofNIH 3T3 cells transfected with flt-3 (Coined et al 1999). They also reported that 
FRIL possessed the ability to preserve hematopoietic progenitors in long-term 
cultures (29 days) without exogenous support of serum or growth factors. In the ex 
vivo expansion system, incubation of CD34+ cells with FRIL resulted in lower 
numbers of cycling cells compared with cytokine-stimulated cells and these cultured 
cells successfully engrafted the NOD/SCID mice (Kollet et al. 2000). 
1.3.3 Ex Vivo Expansion for Clinical Transplantation 
The first attempt of expanding hematopoietic cells for clinical transplantation was 
performed by Naparstek et al (1992) who cultured one-third of allogeneic BM cells 
with GM-CSF and IL-3 for 4 days. These cells, together with the uncultured BM 
cells were infused into 20 patients who were suffering from malignant hematological 
diseases. There was no significant acceleration of neutrophil recovery in these 
patients but a shorter median platelet recovery time was observed when compared to 
historical controls. Subsequently, several clinical trials were performed and the 
details of the expansion systems and outcomes were summarized in Table 1.2. 
Brugger et al. (1995) described the first report on the clinical transplant using 
expanded autologous PBSC without simultaneous infusion of uncultured cells. He 
demonstrated that no toxic effect or side effect was associated with the infusion of 
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expanded cells. The neutrophil and platelet recovery times were 13 and 14 days, 
respectively and were not different from those of historical controls. However, there 
have been concerns that the chemotherapy regimen employed was not myeloablative. 
A similar study was performed by Alcorn et al. (1996) who expanded CD34+ cells 
enriched from cryopreserved PB in serum-free Progenitor-34 medium containing 5 — 
10% autologous serum. Ten patients with nonmyeloid malignancy were infused with 
expanded cells and showed rapid neutrophil and platelet engraftments (10 and 12 
days). However, Holyoake et al (1997) reported that 2 non-Hodgkin's lymphoma 
and 2 multiple myeloma patients who received expanded cells using the same 
cytokine combination failed to show durable engraftment. 
Thrombocytopenia was a significant cause of morbidity in patients undergoing high-
dose chemotherapy and hematopoietic stem cell transplantation (Kessinger et al 
1988, Williams et al. 1990b). Regular platelet transfusions were costly and 
associated with the risk of infectious diseases, alloantibody formation and subsequent 
refractoriness to the transfusion. The rate of platelet recovery correlated with the 
number of infused megakaryocytic progenitors (Leibundgut et al 1995, Takamatsu 
et al 1995, Feng et al 1998). Using a protocol for the expansion of megakaryocytic 
lineage, Bertonlini et al (1997a) reported that two out of four patients receiving the 
highest numbers of infused megakaryocytic progenitors did not require platelet 
transfusion. The median duration of neutrophil and platelet engraftment was 9 and 11 
days, respectively. 
The ex vivo expansion of CB stem and progenitor cells has become a promising 
strategy to overcome the limitation of the small cell dose in a CB unit. Kogler et al. 
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(1999) first reported the expansion of CB CD34+ cells with TPO, FL, G-CSF. 
Expanded cells as well as unmanipulated CD34+ cells were infused into a patient 
who suffered from acute lymphoblastic leukaemia. The neutrophil and platelet 
recovery times were 14 and 75 days, respectively. Subsequently, several trials were 
performed on the clinical expansion of CB hematopoietic progenitor cells (Kurtzberg 
et al 1999, Goldberg e广 al. 2000，Pecora et al. 2000，Shpall et al 2000) and 
favorable results were observed in some studies (Pecora et al 2000, Shpall et al. 
2000). 
Instead of using culture flasks or large-scale culture bags, a perfusion culture system 
was developed by Aastrom Bioscience for clinical BM and CB cell expansion 
(Koller et al 1993, Koller et al 1995, Koller et al 1998, Bachier et al 1999, 
Kurtzberg et al 1999，Goldberg et al 2000, Pecora et al 2000, Stiff 已广 al. 2000). In 
this system, MNC were expanded in FCS-containing long-term culture medium with 
PIXY321 (a fusion protein of GM-CSF and IL-3), FL and EPO for 12 days. Most of 
patients receiving only expanded cells or simultaneously with uncultured cells 
experienced sustained neutrophil and platelet engraftments. No toxicity or side effect 
was observed in them except those reported by Goldbery et al. (1999). In this trial 
using expanded CB cells, 12 out of 19 patients died due to GVHD, sepsis, adenovirus 
infection and central nervous system hemorrphage. 
In other trials, the medium and cytokines (TPO, SCF and G-CSF) of Amgen Inc. 
(Thousand Oaks, CA, USA) were used for the clinical expansion of PBSC and CB. 
Some favorable outcomes were reported (Reiffers et al. 1999, McNiece et al. 1999, 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































absolute and severe neutropenia could be abrogated in 14 multiple myeloma patients 
after high-dose chemotherapy by the infusion of both expanded and uncultured cells. 
Median duration of severe neutropenia was dramatically reduced to 1.5 days (range 0 
—7 days) when compared to historical records. McNiece et al (1999, 2000) 
transplanted expanded cells (from PBSC) and uncultured cells to patients suffering 
from breast cancer and again demonstrated shortened durations of neutrophil 
engraftment but improvements in platelet recovery were not observed. Paquette et al. 
(2000) cultured unselected PBSC mobilized from 24 breast cancer patients. The 
patients had shorter times to neutrophil and platelet recovery and fewer red cell 
transfusions when compared to historical controls. Seven patients had neutropenia 
for 3 or fewer days and 9 patients did not experience neutropenic fevers. The median 
time for platelet recovery was 9.3 days. 
Section 1.4 Non-Obese Diabetic/Severe Combined Immunodeficient 
Mouse Transplantation Model 
It is critical that the stem and progenitor cells produced after ex vivo expansion 
possess the abilities to "home" to the bone marrow and differentiate into functional 
blood cells of different lineages. An in vivo transplant model would be required the 
assessment of such functions. Over the past decade, some mouse mutants have been 
employed for the transplant of human hematopoietic stem and progenitor cells. In 
1983, the severe combined immunodeficient (SCID) mouse, which was homozygous 
for the Prkdcfcid locus, was developed (Bosma et al 1983). These mice were severely 
deficient in functional B and T lymphocytes but readily supported xenogeneic tumors 
and human hematopoietic cells (Bankert et al. 1989, McCune et al 1989, Dick 
1991). Cesano et al (1992) demonstrated that established cell lines and primary 
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samples from patients with acute or chronic myeloid leukemia could be reproducibly 
grown in SCID mice. 
In the SCID/hu model developed by McCune et al. (1988), a human hematopoietic 
microenvironment was created by implanting fragments of human fetal thymus and 
liver (McCune et al. 1988) or bone (Kyoizumi et al. 1992) into CB-\l-scid/scid 
mice. However, the engraftment levels of human cells were low, representing only 
0.5% - 5% of the total recipient marrow population. The murine-origin 
microcnvironmcnl in SCID mice might not be physiologically sufficient to sustain 
human stem cell self-renewal and differentiation. 
Rccemly, SCID mice ha\e been backcrossecl with the non-obcsc diabctic (NOD/I.t) 
mouse background. In addition to lacking T- and B-ccll functions, the rcsiilling 
HOD \.\S/-sci(l/scid (NOD/SCID) mice exhibited low�latLiral killer ccll activity, 
clcfcclivc macrophage function and lacking hemolytic complement (Shiill/. ct al. 
19()5). NOD SCID mice have shown improved cngraftnicnl of human hcmatopoiclic 
cdls ov er SCID mice (Bock ci ul. 1995, Sluill/ ct al. 5. Larochcllc ci al. \')')(), 
N'crluHlcii ci (il. 199S). 
liiiniaii cclls capable of cngrariinu in niicc ucrc icmiccl S('ID-rcpopiilaiiiig cells 
(SRC'I (I apuiol i-i ul l arochcllc ci ul Larochcllc cf al ( 
dcinonslraicd thai most I IC-IC ami C} [‘ were incapahlc engrafting \()I) SCID 
mice, thus pros iding strong cvidcncc thai SR(； u a,s more pnmili\ c aiul a distinct ccll 
popiilalion. SRC ucrc phenol)pically charactcn/cd as (•I)34"('1)38 cells 
(Larochcllc ct ul 1 物”.Rcccnl siiidics dcnionslralcd thai (1)34 ('1)38 cells (Bhaiia 
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et al 1998) and CD34+CD38+ cells (Conneally et al 1997) have limited engraftment 
potential. It has been suggested that there might be two distinct classes of SRC, the 
long-term repopulating cells that had life-long ability to produce all blood cell types 
and the short-term repopulating cells that were either myeloid or lymphoid restricted 
progenitors (Jordan et al 1990, Keller et al. 1990, Magli et al 1982, Kondo et al. 
1997, Akashi et al. 2000). Hogan et al (1997) firstly reported the characterization of 
hematopoietic development of human CB CD34+ cells in NOD/SCID mice. They 
showed that human CB CD34+ cells could consistently engraft in the BM of these 
mice. Over 90% of recipients who survived to the end of the experiment showed 
varying degrees of human cell repopulation. CD34+ cells engrafted and proliferated 
through the hematopoietic tissues such as PB and spleen of NOD/SCID recipients. 
Christiansen et al. (1997) developed a new strain of immunodeficient mice in which 
the residual low natural killer activity present in the NOD/SCID mouse was 
essentially eliminated by backcrossing the p2 microglobulin-null allele onto 
the NOD/SCID background. Both long-term and short-term repopulating cells were 
able to engraft NOD/SCID-p2m"^" mice (Glimm et al 2001), thus allowing the 




The overall objective of this study was to investigate and establish an optimal culture 
system for the ex vivo expansion of cord blood stem and progenitor cells. The 
specific aims were: 
(1) To investigate the effects of flt-3 ligand and stem cell factor on the ex vivo 
expansion of megakaryocytic progenitor cells and the expression of flt-3 
ligand receptors in megakaryocytic cells 
The effects of two early-acting cytokines FL and SCF on the expansion of 
enriched CD34+ cells to megakaryocytic progenitors were assessed in cultures 
containing TPO, IL-3 and IL-6. The read-out system included viable nucleated 
cells, CD34+ cells, CD34+CD38- cells, CD61+CD41+ cells and CFU-MK. The 
expressions of FL receptor were measured on four megakaryocytic cell lines 
and three leukemic bone marrow samples by flow cytometry analysis. 
(2) To study the effects of a novel agent, mannose-binding lectin on the ex vivo 
expansion system and the preservation of primitive progenitors 
An in-house developed plant MBL, in increasing dosage, was included in 
expansion cultures with two cytokine combinations for 14 - 35 days. The read-
out system was CD34+ cells and their CD38" subsets, CFU of the mixed, 
erythroid, myeloid and MK lineages as well as the NOD/SCID mouse 
transplantation model. To investigate the possible property of MBL on the 
preservation of early stem cells, it was included in CB MNC or CD34+ cell 
cultures in serum-free X-Vivo 10 medium without cytokine supplements for 35 
days. The presence of CFU was then determined. 
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(3) To optimize the culture duration, culture media, addition of autologous 
plasma and cytokine combinations for the preclinical ex vivo expansion of 
cord blood CD34+ cells 
The expansions were performed with various treatments: four media, four 




MATERIALS AND METHODOLOGY 
Section 3.1 Collection of Cord Blood Samples 
All CB samples were collected with informed consent and the approval of the Ethics 
Committee for Clinical Research of The Chinese University of Hong Kong. 
CB samples were collected into 30 ml sterile plastic universal containers (Sterilin; 
Stone, UK) containing preservative-free sodium heparin (David Bull Laboratories; 
Victoria, Australia) at a final concentration of 10 lU/ml in RPMI 1640 medium 
(Gibco; Grand Island, NY, USA) supplemented with 100 lU/ml penicillin (Gibco) 
and 100 j^g/ml streptomycin (Gibco). CB was collected from the umbilical vein after 
the umbilical cord was clamped during normal vaginal deliveries of full-term 
newborns. All aspects of cord clamping and placental delivery were at the discretion 
of midwives and clinicians in the labor ward of Department of Obstetrics and 
Gynecology, Prince of Wales Hospital. 
Section 3.2 Cryopreservation and Thawing of Cord Blood 
For some experiments as specified, CB samples were cryopreserved before use. 
Fresh unmanipulated CB samples were mixed with an equal volume of ice-cold 
freezing medium containing 40% RPMI 1640 medium, 40% HSA (Baxter; Glendale, 
CA, USA) and 20% dimethyl sulphoxide (DMSO) (Sigma; St. Louis, MO, USA) in 
freezing bags (Cryocyte, Nexell; Irvine, CA, USA). These bags were then placed in 
protective aluminum canisters and subjected to rate-controlled freezing using a 
controlled rate freezer (CryoMed; New Baltimore, MI, USA). The freezing chamber 
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was cooled at 5°C per min to 4°C and equilibrated for 10 min. It was then cooled at 
2°C per min to -30°C, at 4 � C per min to -100°C and equilibrated for 10 min. 
Subsequently, the bags were transferred into the liquid phase of liquid nitrogen tank 
for storage. 
CB samples were kept in liquid nitrogen for at least 48 hr before use. Thawing of CB 
was performed as described by Rubinstein et al. (1995). CB bags were equilibrated 
in the gas phase of liquid nitrogen for 30 min and then exposed to ambient 
temperature for 5 min to allow the plastic to regain elasticity. The bags were 
immersed in a 37°C water bath immediately and thawed with continuous agitation 
and gentle massage by hand. Usually it took less than 2 min to thaw a whole blood 
unit. The CB was then diluted with an equal volume of washing solution containing 
5% HSA and 10% Dextran 40 (McGaw; Irvine, CA, USA) in 0.9% normal saline and 
centrifuged at 400 x g for 10 min at 4°C. The supernatant was removed and the cells 
were resuspended in fresh washing solution prior to CD34+ cell enrichment. 
Section 3.3 Enrichment of CD34+ Cells 
MNC were first prepared by density gradient centrifugation over Ficoll Hypaque 
(1.077 g/ml) (Amersham Pharmacia; Uppsala, Sweden). Fresh CB samples were 
diluted 1:1 with IMDM (Gibco). Cryopreserved CB samples were thawed, washed 
and resuspended in washing solution to the volume as originally collected. Thirty ml 
freshly diluted CB or thawed CB were carefully layered over 15 ml of Ficoll 
Hypaque and centrifuged without brake at 400 x g for 35 min at room temperature. 
The upper layer was aspirated leaving the MNC layer undisturbed at the interphase. 
The interphase cells were collected carefully. The cells were then washed two times 
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with Ca2+ and Mg2+ free phosphate-buffered saline, pH 7.4 (PBS) (Gibco) 
supplemented with 0.6% acid citrate dextrose formula A (ACD-A) (Baxter; 
Deerfield, IL, USA) and centrifuged at 200 x g for 10 min at room temperature. Cell 
count was performed using a Bright-light hemacytometer (Reichert-Jung, Cambridge 
Instruments Inc.; Buffalo, NY, USA). The viability of cells was evaluated by the 
trypan blue exclusion assay. Cells were diluted 1:4 with 0.1% (w/v) trypan blue 
(Gibco) and dye-excluded cells were counted with the hemacytometer. The viability 
was reported as the percentage of viable cells after counting 400 nucleated cells. 
CD34+ cells were enriched using the MACS CD34 Progenitor Isolation Kit (Miltenyi 
Biotec. Inc.; Gladbach, Germany). According to the manufacturer's instruction, 
MNC were resuspended at 10^ cells per 300 |LI1 in PBS buffer containing 0.6% ACD-
A and 0.5% deionized bovine serum albumin (BSA) (Sigma). All labeling reagents 
provided in the isolation kit were added at 100 jul per 10^ total cells. For the 
processing of less than or more than 10^ cells, the amount of reagents and antibodies 
were adjusted accordingly. The maximum concentration of the cell suspension was 
g 
10 cells per 500 \il The cells were incubated with a FcR blocking reagent (human 
IgG) and simultaneously with anti-human monoclonal hapten-conjugated CD34 
antibody (Clone QBEND/10) for 15 min at 4°C with shaking at 5 min intervals. After 
washing with 10 ml PBS buffer, the cells were incubated with colloidal super-
paramagnetic MACS Microbeads conjugated to an anti-hapten antibody for 15 min at 
4°C with shaking every 5 min. These cells were then washed and resuspended at 10^  
cells per 500 i^l PBS buffer. 
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The positive selection MS+ or VS+ column which could process up to 10^ or 10^ 
cells，respectively was used and placed (with column adaptor) in the magnetic field 
of the Mini or Vario MACS separator. For experiments on the "Effects of flt-3 ligand 
and stem cell factor on the expansion of megakaryocytic progenitor cells" in Section 
3.4.1, MS+ columns and MiniMACS were used while VS+ columns and VarioMACS 
were used in experiments on the "Effects of mannose-binding lectin on the ex vivo 
expansion of hematopoietic stem and progenitor cells" in Section 3.4.2 and 
"Optimization of culture conditions for the preclinical ex vivo expansion of cord 
blood hematopoietic stem and progenitor cells" in Section 3.4.3. The column was 
filled and rinsed with 500 jul (for MS+ column) or 3 ml (for VS+ column) PBS buffer. 
The cells were loaded onto the column. After unbound cells have passed through the 
column, it was washed with 500 |LI1 (for MS+ column) or 3 ml (for VS+ column) PBS 
buffer for three times. The MS+ or VS+ column was then removed from the separator 
and placed on a 6 ml tube (Falcon, Becton Dickinson, BD; Franklin Lakes, NJ, USA) 
or a 12 ml collection tube (Miltenyi), respectively. Retained cells were eluted using 
the plunger with 0.5 ml or 2 ml PBS buffer pipetting onto the MS+ or VS+ column, 
respectively. The eluted cells were applied to a second prefilled column. Enriched 
CD34+ cells were finally obtained by repeating the washing and elution steps. 
The purity of isolated CD34+ cells was evaluated by flow cytometry described in 
Section 3.6 and the viability of cells was determined by the trypan blue exclusion 
assay. 
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Section 3.4 Ex Vivo Expansion 
All culture media were supplemented with 100 lU/ml penicillin and 100 \xg/m\ 
streptomycin. The choice of cytokine combinations was determined by their ability 
to support the expansion of various lineages of progenitor cells. In Section 3.4.1, 
megakaryocytic-specific cytokines were used. In Section 3.4.2, two groups of 
cytokine combinations were employed for the expansion of megakaryocytic and 
early progenitors. In Section, 3.4.3，cytokines of clinical or preclinical grades were 
assessed. Concentrations of cytokines used were based on published data and prior 
dose-response experiments (Luens et al. 1998, McNiece et al. 1999, Murray et al. 
1999, Reiffers et al 1999, Sui et al 1999, Lewis et al 2000，McNiece et al 2000b, 
Paquette et al 2000, Ueda et al 2000, Yang et al. 2000, Su et al. 2001). 
Cytokines used in Section 3.4.1, 3.4.2, 3.5.1 and 3.5.2 were diluted in IMDM DIUS 
lo/o BSA at a concentration of 1 ng/jul. Cytokines in Section 3.4.3 were diluted in 
QBSF-60 serum-free medium (Quality Biological; Gaithersburg, MD, USA) plus 1% 
HSA at a concentration of 5 ng/^il. All cytokines, except those provided by Kirin 
Brewery Co., Ltd. (Tokyo, Japan), were stored in aliquots at - 8 0 � C following 
manufacturer's recommendations. Cytokines provided by Kirin Brewery Co., Ltd. 
were kept at 4 � C after dilution. MBL used in Section 3.4.2 was developed in-house 
from a plant source in the Department of Biology，The Chinese University of Hong 
Kong. Due to possible development of this product for commercial purposes, details 
of its synthesis and characterization were not disclosed. MBL was diluted in IMDM 
plus 1% BSA at a concentration of 10 ng尔 1 and kept at -80°C. 
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3.4.1 Effects of Flt-3 Ligand and Stem Cell Factor on the Expansion of 
Megakaryocytic Progenitor Cells 
3.4.1.1 Ex Vivo Expansion of Cord Blood CD34+ Cells with Flt-3 Ligand or Stem 
Cell Factor 
Enriched CD34+cells at 8 x 10^ were cultured in a 24-well culture plate (Falcon) in 1 
ml IMDM FCS (Gibco) in the presence of 20 ng/ml TPO, IL-3 and IL-6 which were 
megakaryocytic-specific cytokines plus either 20 ng/ml FL or SCF. All cytokines 
were products of Peprotech (Rocky Hill, NJ, USA). The cultures were incubated at 
37°C and 5% CO2 in a fully humidified atmosphere for 21 days. At days 7 and 14, 
three-quarters of cells from each well were harvested for analysis. Equal volumes of 
fresh medium and cytokines were added. At day 21, all cells were harvested for 
analysis. Seven independent CB cultures were performed. 
At each time point, cell counts, viability, flow cytometry analysis and CFU-MK 
colony assay were performed. The total nucleated cell count was calculated by 
multiplying the number of nucleated cells per ml by the volume of cells. After 
counting the number of cells on the eight quadrants of the hemacytometer, number of 
nucleated cells per ml was obtained by the equation: 
cell count 
X dilution factor x\Q . The fold expansion of total nucleated cells was 
calculated by dividing the number of nucleated cells after culture by the number of 
nucleated cells at day 0. The percentages of CD34+, CD34^CD38" and CD61+CD41 + 
cells were determined by flow cytometry as described in Section 3.6. 
Assay of CFU-MK was performed using the methylcellulose system (Li et al. 2000). 
Enriched CD34+ cells or expanded cells at 3 x 10^/ml were cultured in triplicate in 
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1% methylcellulose (Sigma) in IMDM supplemented with 20 ng/ml TPO, 30% FCS, 
1% BSA and 0.1 mM P-mercaptoethanol (P-ME) (Gibco). The cultures were 
incubated for 12 days. The colonies were examined under an inverted microscope. A 
CFU-MK colony was defined as a cluster of three or more megakaryocytes (Yang et 
al 1995). 
3.4.1.2 Flt-3 Ligand Receptor Assay 
3.4.1.2.1 Culture of Human Megakaryoblastic Cell Lines 
Four human megakaryoblastic cell lines, Meg-01，CHRF-288-11, Dami and M-07e, 
were cultured in IMDM containing 10% FCS. IL-3 at 25 ng/ml (Genzyme; 
Cambridge, MA, USA) was added to M-07e. All cultures were maintained at 37�C in 
a 5% CO2 humidified incubator. When the cell densities of cultures reached 1 x 
lOVml, cells were washed with IMDM without FCS and centrifuged at 200 x g for 10 
min at 4�C. Cells were then cultured in IMDM with 10% FCS at 5 x loVml. 
3.4.1.2.2 Identification of Flt-3 Ligand Receptors 
Four cultured cell lines and MNC from three pediatric acute lymphoblastic leukemia 
patients at 5 x 10' per 100 jil were stained with phycoerythrin (PE)-conjugated 
mouse anti-human FL receptor monoclonal antibody (Immunolech; Marseille, 
France). MNC from acute lymphoblastic leukemia patients were obtained by density 
gradient centrifugation over Ficoll Hypaque. Another 5 x 10' cells of each sample 
wei-e stained with isotypic IgG control (Immunotech). All samples were incubalcd 
for 20 min in the dark at room temperature. They were washed with 2 ml PBS and 
centrifuged at 200 x g at 20''C for 6 min. Twenty thousand events were acquired for 
each sample. These cells were analyzed using a FACScan flow cytometer and the 
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Lysis II software (BD). Cell debris was excluded by gating on the forward and side 
scatter profile during data analysis. 
3.4.2 Effects of Mannose-Binding Lectin on the Ex Vivo Expansion of 
Hematopoietic Stem and Progenitor Cells 
3.4.2.1 Ex Vivo Expansion of Cord Blood CD34+ Cells with Mannose-Binding Lectin 
Enriched CD34+ cells from eight CB samples at 2 x \ if/m\ were cultured in a 24-
well culture plate in 1 ml IMDM supplemented with 10% FCS. Two groups of 
cytokine treatments were used: (A) for the megakaryocytic lineage: 50 ng/ml TPO, 
25 ng/ml SCF, 20 ng/ml IL-ip, 25 ng/ml IL-6 and 25 ng/ml IL-11; (B) for the early 
progenitor cells: 50 ng/ml TPO, 25 ng/ml SCF and 50 ng/ml FL. MBL at 0, 50, 100, 
200, 400 and 800 ng/ml were added to the cultures in both groups (A) and (B). The 
cultures were incubated at 37°C and 5% CO2 in a fully humidified atmosphere for 35 
days. At days 7, 14, 21 and 28, half of cells from each culture was harvested and 
topped up with the same volume of fresh medium and cytokines. Cell counts, 
viability, flow cytometry analysis (CD34+，CD34+CD38- and CD61+CD41+ cells) and 
colony-forming assays as described in Section 3.5 were performed at days 14，21, 28 
and 35. 
3.4.2.2 Effects of Mannose-Binding Lectin on the Preservation of Early Stem and 
Progenitor Cells 
MNC at 2 X 10^/ml or enriched CD34+ cells at 2 x loVml were cultured in a 25 cm^ 
flask (Coming; New York, NY, USA) in 5 ml X-Vivo 10. In each culture, 100, 200, 
400, 800, 1600 ng/ml MBL, 40 ng/ml FL, 40 ng/ml FL plus 200 ng/ml MBL were 
added. The cells cultured in the absence of MBL and FL were used as the control. 
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The cultures were incubated for 35 days without any medium changes. At days 14, 
21, 28 and 35, 1 ml of cells were harvested for cell counts, cell viability test and 
colony-forming assays. Eight independent CB cultures using MNC or CD34+ cells 
were performed. 
3,4.2.3 Transplantation of Expanded Cells into NOD/SCID Mice 
Enriched CD34+ cells at 2 x \(flm\ from nine fresh CB samples were cultured in 5 
ml IMDM + 10% FCS in the presence of 50 ng/ml TPO, 25 ng/ml SCF and 50 ng/ml 
FL with or without 200 ng/ml MBL for 14 days. At day 7, another 5 ml fresh 
medium with cytokines were added to the cultures. Cells were harvested at day 14 
and transplanted into NOD/SCID mice. The transplantation of expanded human cells 
into NOD/SCID mice was described in details in Section 3.7. 
3.4.3 Optimization of Culture Duration, Culture Media, Autologous Plasma 
and Cytokine Combinations for the Preclinical Ex Vivo Expansion of 
Hematopoietic Stem and Progenitor Cells 
3-4.3.1 Comparison of Culture Duration, Culture Media and Cytokine Combinations 
Ten independent CB cultures were performed for the comparison of culture duration, 
various media and cytokine combinations. Enriched CD34+ cells at 2 x lO'^ /ml were 
cultured in a 24-well culture plate. The four media being assayed were IMDM 
supplemented with 10% FCS, X-Vivo 10 (Biowhittaker; Walkersville，MD, USA), 
QBSF-60 and StemSpan SFEM (Stem Cell Technologies; Vancouver, BC, Canada). 
The latter three media were serum-free and were supplemented with 1% HSA, 2 mM 
L-glutamine (Gibco) and 0.1 mM P-ME. As recommended by the manufacturer, 40 
fag/ml low density lipoprotein (Sigma) was added into StemSpan medium. For this 
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preclinical study, cytokines of clinical or preclinical grades were assessed. Five 
cytokines were used: 50 ng/ml TPO, 50 ng/ml SCF, 80 ng/ml FL, 40 ng/ml G-CSF 
and 100 ng/ml IL-6. The four cytokine combinations were TPO, SCF and FL (TSF), 
plus either G-CSF (TSFG), IL-6 (TSF6) or both cytokines (TSFG6). All cytokines 
were purchased from Peprotech, except for G-CSF which was purchased from Roche 
(Neupogen; Basle, Switzerland). The cultures were incubated at 37�C and 5% CO2 in 
a fully humidified atmosphere for 12 days. At days 4 and 8, each culture was split 
into three portions and topped up with the same volume of fresh media and 
cytokines. Cell counts, viability, flow cytometry analysis (CD34+, CD34+CD38-, 
CD61+CD41+ cells) and colony-forming assays were performed at days 8 and 12. 
3.4,3.2 Effects of Autologous Cord Blood Plasma 
Another six CB cultures were performed to investigate the effects of autologous CB 
plasma on the expansion of CD34+ cells. In addition to the same media and cytokine 
conditions described in Section 3.4.3.1, 10% autologous CB plasma was included in 
the three serum-free media. In the IMDM cultures, 10% FCS was replaced by 10% 
autologous CB plasma. To obtain autologous CB plasma, 10 ml of each CB sample 
was centrifuged at 3,000 x g for 15 min at room temperature. After the collection of 
supernatant, the plasma was stored at - 20�C and heat inactivated at 56�C for 30 min 
before use. 
Effects of Flt-3 Ligand and Dosage of Thrombopoietin and Stem Cell Factor 
Eight independent CB cultures were performed to elucidate the effects of FL and 
different doses of TPO and SCF on the expansion outcomes. Enriched CD34+ cells at 
2 X lOVml were cultured in QBSF-60 in the presence of TPO and SCF at 50 ng/ml or 
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100 ng/ml, 40 ng/ml G-CSF, with or without 80 ng/ml FL for 12 days. At days 4 and 
8, cultures were split into three portions and topped up with two-third volume of 
fresh medium and cytokines. At days 8 and 12，expanded cells were harvested for 
analysis. The same parameters as those in Section 3.4.3.1 were analyzed. 
3.4.3.4 Transplantation of Expanded Cells into NOD/SCID Mice 
Enriched CD34+ cells from five cryopreserved CB at 2 x lO'^ /ml were cultured in 
QBSF-60 with 50 ng/ml PEG-MGDF (Kirin), 50 ng/ml rhSCF (Kirin)，40 ng/ml G-
CSF, with or without 80 ng/ml FL for 12 days. Expanded cells were then 
transplanted into NOD/SCID mice studying the effects of FL on the engrafting 
ability of hematopoietic stem and progenitor cells. 
Section 3.5 Progenitor Colony-Forming Assays 
3.5.1 Colony-Forming Unit Assay 
Colony-forming unit granulocyte-macrophage (CFU-GM), burst-forming 
unit/colony-forming unit erythroid (BFU/CFU-E) and colony-forming unit 
granulocyte-erythroid-macrophage-megakaryocyte (CFU-GEMM) were assayed in 
lo/o methylcellulose culture in IMDM supplemented with 30% FCS, 1% BSA and 0.1 
mM p-ME in the presence of 3 Ul/ml EPO (Eprex, Cilag; Zug, Switzerland), 10 
ng/ml GM-CSF (Leucomax; Basle, Switzerland), 10 ng/ml IL-3 (Peprotech) and 50 
ng/ml SCF (Peprotech). Enriched or expanded CD34+ cells at 3 x loVml, or fresh or 
expanded MNC at 5 x lOVml were seeded in triplicate and incubated for 14 days. 
Colonies were scored using an inverted light microscope by their morphology. 
Colonies of more than 50 cells were counted as a CFU and the following categories 
of CFU were classified (Eaves et al. 1995). 
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(i) CFU-GM 
Clonogenic progenitors of granulocytes and macrophages (CFU-GM) were defined 
on the basis of their ability to produce colonies containing 50 or more of these cells. 
Morphologically, CFU-GM showed a relatively flat, non-hemoglobinized and 
homogeneous morphology, often with a more concentrate central core of 
granulocytes surrounded by a less dense halo of macrophages. 
(ii) BFU/CFU-E 
BFU-E was distinguished by its greater proliferative capacity of giving rise to larger, 
densely packed, multi-clustsered erythroid colonies when compared to those 
produced from CFU-E. It was orange to dark red hemoglobinized cells with no 
appearance of translucent cells. A BFU-E colony was identified as 5 or more clusters 
of cells. 
CFU-E-derived colonies were identified as one or two clusters containing up to a 
maximum of approximately 100 to 200 erylhroblasls. Each cluster contained a 
minimum of eight erythroblasts. The erylhroblasls were recognized as a distinctive 
reddish-orange hue due to their content of hemoglobin. 
(ill) CFU-GEMM 
CFU-GEMM was identified as colonies containing cells of multiple lineages 
appeared as small numbers of granulocytes, macrophages and/or megakaryocytes 
around tlic periphery of a sphcrical mass of hemoglobini/cd erythroid cclls. CFL-
GEMM were examined under high power, to avoid being mistakenly scorcd as pure 
erythroid colonies. 
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3.5.2 Colony-Forming Unit-Megakaryocyte 
CFU-MK, unless specified, was assayed using a plasma clot system. Enriched or 
expanded CD34+ cells at 3 x loVml, or fresh or expanded MNC at 5 x lO'^ /ml were 
grown in duplicate in IMDM containing 10% citrated bovine plasma (Sigma), 10% 
FCS, 1% BSA, 0.1 mM p-ME, 0.34 mg/ml calcium chloride in the presence of 50 
ng/ml TPO and 20 ng/ml IL-3. After 12 days of incubation, the clots were air-dried 
and fixed with 1% paraformaldehyde (Sigma) pH 7.4 in PBS. They were stored at 
4°C before scoring. Immunofluorescence staining was performed by labeling with 
monoclonal antibody CD61-fluorescein isothiocyanate (FITC) (Dako; Boston, MA, 
USA) (Kratz-Albers et al 2000). The clots were rinsed with 3 ml PBS with 0.5% 
BSA. CD61-FITC monoclonal antibody was diluted 1:10 in PBS and 500 |LI1 diluted 
antibody was then added onto the clots and incubated in the dark at room 
temperature for 20 min. The clots were rinsed with 3 ml PBS with 0.5% BSA. CFU-
MK was identified as a cluster of three or more strongly-stained CD61 positive cells 
examined under a fluorescent microscope. 
3.5.3 Calculations of CFU 
The number of CFU generated from the culture was calculated by the equation: 
total nucleated cells 
X no. of colonies formed. 
no. of cells seeded 
The fold expansion of CFU was obtained by dividing the number of CFU after 
expansion by the number of CFU at day 0. 
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Section 3.6 Flow Cytometry Analysis 
At day 0, 1 x 10^ enriched CD34+ cells were stained with 10 |il each of CD34-FITC 
(Clone 8G12) (BD; San Jose, CA, USA), CD38-phycoerythrin (PE) (BD) and 
respective isotypic control monoclonal antibodies (BD). CD34-FITC monoclonal 
antibody (Anti-HPCA-2) recognized different epitopes of the CD34 antigen from 
that recognized by the monoclonal antibody QBEND/10 used in Section 3.3 for 
CD34+ cell enrichment. The cells were incubated in the dark for 20 min at room 
temperature. After incubation, 2 ml PBS with 0.5% BSA was added. The cells were 
centrifuged at 200 x g at room temperature for 6 min and resuspended in 0.5 ml 1% 
paraformaldehyde (Sigma) in PBS pH 7.4. Fixed cells were analyzed within 30 min 
or stored at 4°C for less than 4 hr before acquisition. Thirty thousand events were 
acquired using a FACSCalibur flow cytometer (BD) for the determination of the 
purity of enriched CD34+ cells. These results were analyzed using the CellQuest 
software (BD) with dead cells and debris gated out by the forward and side scatter 
profiles. 
After expansion, cultured cells were washed with PBS containing 0.5% BSA and 
centrifuged at 300 x g at room temperature for 10 min. Cells were resuspended in 
100 jjl PBS and stained with 10 each of CD34-FITC/CD38-PE (BD), CD61-
FITC/CD41-PE (Dako), and their respective isotypic controls for 20 min in the dark 
at room temperature. Cells were then washed and resuspended in 100 PBS. Prior 
to analysis, 10 |il 7-amino-actinomycin D (7-AAD) (Pharmingen) was added to each 
sample and incubated for 10 min in the dark at room temperature. Samples were 
washed with 2 ml PBS and centrifuged at 200 x g for 6 min at room temperature. 
The cells were resuspended in 500 |LI1 1% paraformaldehyde. Sixty thousand events 
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were acquired for each sample. These cells were analyzed using a FACSCalibur flow 
cytometer and the CellQuest software (BD). Dead cells which were 7-AAD positive 
were gated out during data analysis. 
The absolute numbers of CD34+, CD34+CD38- and CD61+CD41+ cells were 
calculated by multiplying their respective percentages obtained from flow cytometry 
analysis by number of total nucleated cells. Their fold expansion was calculated by 
dividing their numbers after culture by the numbers at day 0. 
Section 3.7 Transplantation of Non-Obese Diabetic/Severe 
Combined Immunodeficient Mice 
This study was approved by the Animal Research Ethics Committee of The Chinese 
University of Hong Kong. Non-obese diabetic/severe combined immunodeficient 
(NOD/SCID) mice, which were characterized by the lack of mature lymphocytes, 
macrophage dysfunction, and an absence of circulating complements (Koyanagi et 
al 1997), were obtained from The Walter and Eliza Hall Institute of Medical 
Research, Victoria, Australia. The mice were bred in microisolator cages in the 
Laboratory Animal Services Centre at The Chinese University of Hong Kong. These 
animals were housed in laminar flow racks under pathogen-free conditions and fed 
with autoclaved food and water. At 6 - 8 weeks of age, the mice were exposed to 300 
cGy of gamma irradiation using the Gammacell-1000 Elite Irradiator (MDS Nordion, 
Kanata, On, Canada). They were weighed and anesthetized with a mixture of 
ketamine at 50 mg per kg of body weight and xylazine HCl at 25 mg/kg by 
intraperitoneal injection. The cells for transplantation were washed with IMDM and 
centrifuged at 300 x g at room temperature for 10 min. These cells at 1 x loVml were 
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resuspended in 1ml IMDM. Then, 2 - 4 x enriched CD34+ cells or expanded 
cells which were derived from 2 — 4 x lO* cells at day 0 were injected into the lateral 
tail vein of the mice. 
After 6 weeks, the mice were sacrificed by cervical dislocation. BM (equivalent of 2 
femurs), PB and spleen were collected for analysis. Single-cell suspension of BM 
was prepared by aspirating the femurs with PBS containing 5% FCS to release BM 
cells followed by sedimentation to get rid of clumps and debris. Cells were then 
processed for flow cytometry analysis, PGR and CFU assays. The spleen of each 
transplanted mice was homogenized in PBS containing 5% FCS before cell 
harvesting. PB was collected by heart puncture. Red blood cells were lyzed with 
0.9% ammonium chloride for 5 min. Cells were then washed and resuspended in 
PBS containing 5% FCS for flow cytometry analysis. 
Section 3.8 Assessment of Human Cell Engraftment in Transplanted 
NOD/SCID Mice 
3.8.1 Flow Cytometry Analysis 
Cell samples at 5 x 10-V200 |al in PBS containing 5% FCS were incubated with 10 \i] 
mouse anti-human CD45-phycoerythrin-cyanine 5-succinimidylester (PC5) antibody 
(Immunotech) and propidium iodide (PI) at 10 fig/ml (Sigma) for 20 min in the dark 
at room temperature. The control tube contained the isotypic antibodies 
(Immunotech) and PI. After washing with PBS, cells were analyzed on a FACScan 
Flow Cytomeler (BD) using the Lysis II program with the non-viable cells (PI 
positive) being gated out. Specific subsets of human hematopoietic cells were 
determined when BM cells contained more than 1 % of human CD45" cells. Cell 
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samples were stained with 10 i^l CD45-PC5, PI and CD34-FITC, CD33-F1TC, 
CD14-FITC, CD19-FITC or CD61-FITC. CD33-FITC, CD14-FITC and CD19-FITC 
monoclonal antibodies were purchased from Pharmingen. All antibodies were tested 
to be non-cross-reactive with the NOD/SCID mouse surface antigens. Seventy-eight 
thousand events were acquired for each sample. 
3.8.2 PCR Analysis 
To confirm the engraftment of human cells in a murine background, genomic DNA 
from mouse BM cells was extracted by a DNeasy DNA purification kit (Qiagen, 
Hilden, Germany). BM cells were collected and washed with PBS. The supernatant 
was discarded. Cell pellets were stored at -80°C before extraction. Cells were thawed 
at room temperature until the pellet can be dislodged by gently flicking the tube. 
According to the manufacturer's instruction, 5 x 10^ BM cells were centrifuged at 
300 X g for 5 min at room temperature and resuspended in 200 |LI1 PBS. Twenty |LL1 
proteinase K and 200 |LI1 Lysis Buffer AL were added to the sample, mixed 
thoroughly by vortexing and incubated at 70�C for 10 min. The buffer was optimized 
to allow direct cell lysis. After incubation, 200 i^l absolute ethanol was added to the 
lysate. Wide pore pipette tips were used from this step onwards to avoid the genomic 
DNA from breaking down. The lysate was then loaded onto a spin column sitting in 
a 2 ml collection tube and centrifuged at 6,000 x g for 1 min at room temperature. 
Extracted DNA was able to bind to the silica-gel membrane inside the column. The 
collection tube and the flow through materials were discarded. The column was 
placed in another 2 ml collection tube and 500 j^ l Buffer AWl was added. It was 
centrifuged at 6,000 x g for 1 min at room temperature. The collection tube and the 
flow through were again discarded. The column was put in another 2 ml collection 
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tube. Buffer AW2 (500 |LI1) was added this time. The column was centrifuged at 
20,000 X g for 3 min at room temperature. It was removed and placed in a 1.5 ml 
microcentrifuge tube. Buffer AE (200 |LI1) was pipetted onto the membrane of the 
column followed by a 1 min incubation at room temperature. Buffer AE was used to 
dissolve DNA bound to the membrane. The column was centrifuged at 6,000 x g for 
1 min to elute dissolved DNA. Another 200 jul Buffer AE was added to the 
membrane. The incubation and centrifugation steps were repeated to elute residual 
DNA. 
The presence of human-specific DNA in BM of transplanted mice was confirmed by 
polymerase-chain reaction (PGR) amplification using primers complementary to the 
sequence of an 850-bp DNA fragment of the human-specific alpha satellite DNA of 
chromosome 17 (Waye et al 1986). Amplification of the centromere-specific human 
fragments of chromosome 17 was performed using primers corresponding to the 
primer pair 17al/17a2 as described by Warburton et al (1991). The 5' primer (5, 
GGG ATA ATT TCA GCT GAC TAA ACA G 3，) covered the positions 15 to 39, 
and the 3' primer (5' TTC CGT TTA GTT AGG TGC AGT TAT C 3，) covered the 
positions 867 to 891 of the sequence HSSATA17 (Gene Bank #M13882). For PGR, 
Taq polymerase and reagents were purchased from Gibco. The PGR reaction 
contained IX PGR buffer, 200 I L IM dNTP, 250 nM of each primer, 2 mM MgCl� and 
250 ng genomic DNA (Mobest et al 1999). Samples were initially denatured at 94°C 
for 10 min. Amplification began with denaturation at 94°C for 1 min, 66°C annealing 
for 1 min, 72°C extension for 1 min for 35 cycles, followed by final elongation at 
72°C for 10 min. Genomic DNA samples from human CB and BM cells of non-
transplanted NOD/SCID mouse were processed in parallel as positive and negative 
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controls, respectively. For the positive control, 0.1, 1.0, 5.0, 10.0, 30.0，50.0% of 
human CB DNA mixed with mouse DNA were included as a set of standards. 
Amplified PCR products were electrophoresed through 1.75% agarose gels in IX 
TAE buffer (0.04M Tris-acetate, O.OOIM EDTA pH8) with the power supply of 100 
Volts for 45 min. The agarose gel was pre-stained with ethidium bromide before 
electrophoresis and visualized under ultraviolet light. 
Section 3.9 Statistical Analysis 
The SigmaStat software (Jandel Scientific Software, San Rafael, CA) was used for 
statistical analysis. For the comparison of the effects of FL and SCF on the expansion 
of megakaryocytic progenitor cells and the optimization of culture conditions, paired 
t-test was used in case of normal distribution or Wilcoxon Sign Rank test was used in 
case of non-parametric distribution. One-way ANOVA and paired t-test or Wilcoxon 
Sign Rank test, whichever suitable, were performed for investigating the effects of 
MBL on the ex vivo expansion of hematpoietic stem and progenitor cells. A p-value 
equal to or less than 0.05 was considered as statistical significant. Data were 
expressed as mean 士 standard error of mean (S.E.). 
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CHAPTER FOUR 
EFFECTS OF FLT-3 LIGAND AND STEM CELL 
FACTOR ON THE EXPANSION OF 
MEGAKARYOCYTIC PROGENITOR CELLS 
Section 4.1 Results 
4.1.1 Ex Vivo Expansion of CD34+ Cells 
At day 0, the purity of enriched CD34+ cells were 87.3 士 4.60o/o (range 88.7 - 99.1%) 
(Figure 4.1) and the viability of CD34+ cells as determined by the trypan blue dye 
exclusion assay was 99.0 土 0.44o/o (range 97.0 — 100%). At days 7, 14, and 21, cell 
viability were 95.7 士 0.49o/o (range 94.0 — 98.0%), 95.8 士 0.72 (range 93 - 98.5%) 
and 94.5 士 0.79% (range 91.8 — 97.7%), respectively. Enriched CD34+ cells were 
significantly expanded in the presence of FL or SCF, in combination with TPO, IL-3 
and IL-6. There were overall increases of nucleated cells, CD34+ cells, CD34^CD38' 
cells, CD61+41+ cells as well as CFU-MK. Replacing FL with SCF significantly 
reduced the levels of all cell parameters. 
Total Nucleated Cells 
The expansion of total nucleated cells was in general more efficient in cultures 
containing FL when compared to those containing SCF (Table 4.1). The fold 
increases of total nucleated cells in cultures with FL were 114%, 128% and 231% of 
those with SCF at days 7, 14，and 21, respectively. The number of total nucleated 
cells expanded in FL-containing culture was significantly higher than that in SCF-
containing culture at day 21 (p - 0.0417) (Figure 4.2). 
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CD34+ Cells and CD34''CD38' Cells 
The percentage of CD34+ cells decreased with the duration of culture. An increase in 
absolute numbers of CD34+ cells was seen at day 14 (Table 4.1). Significantly higher 
percentage (p = 0.005) (Figure 4.3) and fold increase (p = 0.0273) (Figure 4.4) of 
CD34+ cells were observed in cultures with FL at day 14 when compared to those 
with SCF. At day 21, the fold increase of CD34+ cells in cultures with FL was also 
significantly higher than that with SCF (p = 0.0159) (Figure 4.4). The yields of 
CD34+ cells in cultures with FL were 123%, 212% and 299% of those with SCF. 
FL supported more efficient expansion of early progenitors than SCR A significant 
difference was observed in the fold increase of CD34^CD38" cells at day 7 (p = 
0.0195) (Figure 4.5) and the same trend was observed at day 14 (p = 0.0658) and at 
day 21 (p = 0.0683) (Table 4.1 and Figure 4.3). The fold increases of CD34+CD38-
cells in cultures with FL were 173 - 468% of those with SCR 
Megakaryocytic Progenitors 
For the megakaryocytic lineage, significant differences were observed in the yield of 
CD61+CD41+ cells (p = 0.0283) (Table 4.1) and the fold increase of CFU-MK at day 
14 (p = 0.0166) (Figure 4.6). FL appeared to support better expansion of 
megakaryocytic progenitors than SCR CD61+CD41+ cells (Figure 4.7) and CFU-MK 
in FL-containing cultures were 136 - 182% and 226 一 200% of those in SCF-
containing cultures, respectively (Table 4.1). 
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Duration of Culture 
The culture for 14 days appeared to be the most effective duration for the expansion 
of both primitive and megakaryocytic progenitors (Table 4.1). The absolute numbers 
of CD34+ cells, CD34^CD38" cells, CD61+CD41+ cells and CFU-MK peaked at day 
14. Instead of being depleted, CD34+ cells increased to 23.8- and 10.7-fold in 
cultures with FL and SCF respectively whereas CD34^CD38' cells increased to 33.9-
and 10.7-fold after 14 days of culture. CD61+CD41+ cells cultured with FL and SCF 
were 15.6% and 9.78% of the total cell populations at day 14 (Figure 4.7). The 
efficiency of the culture system was again demonstrated by the 584-fold increase of 
CFU-MK in cultures with FL at day 14 (Figure 4.6). 
4.1.2 Identification of Flt-3 Ligand Receptors 
The expressions of FL receptor on four megakaryoblastic cell lines and bone marrow 
cells from three pediatric acute lymphoblastic leukemia patients were investigated by 
flow cytometry. As shown in Figure 4.8, all four cell lines did not show any positive 
expression of FL receptors while one leukemic sample expressed a high level of 
receptors. 
Section 4.2 Discussion 
The effectiveness and possible mechanism of using FL and SCF, in combination with 
TPO, IL-3 and IL-6 on the ex vivo expansion of cord blood CD34+ cells to the 
megakaryocytic lineage were studied. Results indicated that FL was significantly 
more effective than SCF in the overall expansion of hematopoietic cells including 
early progenitors and megakaryocytes. 
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Bertolini et al (1997a) reported the clinical transplant of expanded PBSC and 
demonstrated that platelet transfusion support was not required in patients who 
received the highest doses of cultured CD61+ cells. In our system, FL plus TPO, IL-3 
and IL-6 could support up to 584-fold increase of CFU-MK at day 14 of culture. 
CD61+CD41+ cells were over 15% of total nucleated cells in the culture, representing 
a substantial proportion of megakaryocytic progenitors. The data compared favorably 
with those reported by other groups using different cytokine combinations and cell 
sources (Piacibello et al 1996b, Bertolini et al. 1997a, Williams et al 1998, 
Lefebvre et al 2000, van den Oudenrijn et al. 2000). They reported the expansion of 
CFU-MK from 17- to 200-fold. 
Previous studies showed that the expansion outcomes of megakaryocytic progenitors 
were influenced by the source of CD34+ cells (van den Oudenrijn et al 2000) and 
cytokine combinations (van den Oudenrijn et al 1999, Drayer et al 2000, Lefebvre 
et al. 2000, Su et al. 2001). Reports on effects of FL and SCF on the expansion of 
hematopoietic cells to the megakaryocytic lineage have not been consistent (Shapiro 
et al 1996, Ohmizono et al 1997，Williams et al 1998). Ohmizono et al. (1997) 
demonstrated that FL-containing cultures with TPO, IL-3 IL-6 and IL-11 produced 
more CFU-MK when compared with SCF-containing cultures. However, Williams et 
al- (1998) observed better expansion efficiencies using SCF in cultures with TPO, 
IL-1, IL-6 and IL-11. In our culture system using enriched CB CD34+ cells, FL was 
superior to SCF in the expansion of CD61+CD41+ cells and CFU-MK. 
The yields of both early and megakaryocytic progenitors peaked at day 14. The 
prolonged expansion to 21 days increased total nucleated cells but reduced CD34+ 
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cells，CD61+CD41+ cells and CFU-MK. It was significant that our culture conditions 
promoted the expansion of megakaryocytic progenitors and simultaneously expanded 
CD34+ cells and CD34^CD38' cells to 23.8- and 33.9-fold, respectively. In our 
culture conditions, FL significantly improved the expansion of CD34+ cells when 
compared to SCF (Figure 4.4). Our findings are in agreement with those ofKobari et 
al (1998) who demonstrated that the expansion of BM CD34+ cells was increased by 
4.4-fold when FL was added to the culture system with SCF, IL-3 and IL-6. 
Capmany et al. (1999) also reported that the addition of FL to the same cytokine 
combination increased the expansion of CB CD34+ cells by 2.7-fold. Piacibello et al. 
(1997) described a culture system with two cytokines, FL and TPO, which was 
capable of sustaining proliferation and renewal of primitive progenitors for more 
than six months. 
The mechanism of FL on the megakaryocytic lineage remains unclear. Ratajczak et 
al. (1996) and Turner et al. (1996) showed that FL alone or in combination with 
cytokines such as TPO had no effect on in vitro megakaryocytopoiesis and 
megakaryocyte ploidy. In addition, the flt-3 knockout mice did not show any defects 
in megakaryocyte and platelet production (Mackarehtschian et al 1995). Considering 
the lack of FL receptors on four megakaryocytic cell lines, the effect of FL on 
promoting expansion of megakaryocytic progenitors might possibly be mediated by 
its early action at the multipotent stem cell stage. It has been suggested that early 
hematopoietic cells (CD34^CD38" cells) were more responsive to FL than committed 
progenitor cells (CD34+CD38+ cells) (Dooley et al. 1997). 
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In summary, our data demonstrated that in comparison with SCF, FL was a more 
effective cytokine for augmenting TPO, IL-3 and IL-6 on the expansion of CB 
CD34+ cells to megakaryocytic progenitors. The conditions did not deplete primitive 
progenitors, thus representing a potentially useful system for the clinical application 
of expanding CB hematopoietic stem and progenitor cells for BMT. 
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Figure 4.1 Flow Cytometry Analysis: Determination of the Purity of CD34+ 
Cells after Enrichment 
Enriched CD34+ cells were stained with CD34-FITC (FLl) and 
CD38-PE (FL2) monoclonal antibodies. Cells in the upper and lower 
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Figure 4.2 Effects of FL and SCF on the Fold Increase of Total Nucleated 
Cells 
Enriched CD34+ cells at 8 x 10^/ml were cultured in 1 ml IMDM + 
10% FCS in the presence of TPO, IL-3, IL-6 plus either FL or SCF, 
each at 20 ng/ml for 21 days. FL supported more efficient expansion 
of total nucleated cells when compared with SCF. Results were 
presented as mean 土 S.E. n = 7，* p < 0.05. 
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Figure 4.3 Flow Cytometry Analysis of Expanded Cells: Determination of 
the Percentages of CD34+ Cells and Subsets 
Cells were expanded in cultures with FL (C) or SCF (D). Cell debris 
were gated out using their FCS/SSC profile (A). CD34+ cells and 
CD34+CD38- cells were determined by their binding to CD34-FITC 
and CD38-PE antibodies (C & D) in comparison with the respective 
isotypic controls (B). 
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Figure 4.4 Effects of FL and SCF on the Fold Increase of CD34+ Cells 
CD34+ cells were cultured in either FL or SCF with TPO, IL-3 and 
IL-6 for 21 days. CD34+ cells were analyzed by flow cytometry. Fold 
increases of CD34+ cells in FL cultures were significantly higher than 
those in SCF cultures at days 14 and 21. Results were presented as 
mean 士 S.E. n = 7, * p < 0.05. 
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Figure 4.5 Effects of FL and SCF on the Fold Increase of CD34 CD38 Cells 
CD34+ cells were cultured in either FL or SCF with TPO, IL-3 and 
IL-6 for 21 days. CD34^CD38' cells were analyzed by flow 
cytometry. The fold increase of CD34^CD38' cells in the presence of 
FL was significantly higher than that in the presence of SCF at day 7. 
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Figure 4.6 Effects of FL and SCF on the Fold Increase of CFU-MK 
CD34+ cells were cultured in either FL or SCF with TPO, IL-3 and 
IL-6 for 21 days. CFU-MK assay was performed by planting 3 x lO" 
cells per ml onto methylcellulose medium. Fold increases of CFU-
MK in FL cultures was significantly higher than that in SCF cultures 
at day 14. Results were presented as mean 土 S.E. n = 7，* p < 0.05. 
65 
；赛 1 “ , Jr 一〜 jjr 
FSC-HvFSC-Hel^ t —-> F U 知 t g h t — FLi-H'-FLm i^aht > 
(A) (B) (C) 
Figure 4.7 Flow Analysis of Expanded Cells: Determination of the 
Percentage of Megakaryocytic CD61+CD41+ Cells 
Expanded cells were stained with CD61-FITC (FLl) and CD41-PE 
(FL2) monoclonal antibodies. (B) represented FL-expanded cells and 
(C) represented SCF-expanded cells. Cell debris were gated out in 
their FSC-SSC dot plots (A). CD61+CD41+ cells were presented in the 
upper right quadrant. 
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Figure 4.8 Flow Cytometry Analysis of Flt-3 Ligand Receptor on 
Megakaryocytes 
Four human megkaryoblastic cell lines, M-07e, CHRF, Meg-01 and 
Dami, were stained with PE-conjugated anti-human FL receptor 
antibody. A human B-cell ALL sample was analyzed as a positive 
control of the antibody. Dark areas of histograms represented samples 
stained with the antibody and open areas represented samples stained 
with isotypic control. Results showed that the four cell lines did not 
express the receptor. 
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CHAPTER FIVE 
EFFECTS OF MANNOSE-BINDING LECTIN ON THE 
EX VIVO EXPANSION OF HEMATOPOIETIC STEM 
AND PROGENITOR CELLS 
Section 5.1 Results 
5.1.1 Ex Vivo Expansion of CD34+ Cells with Mannose-Binding Lectin 
To study the effects of MBL on the ex vivo expansion of CB hematopoietic stem and 
progenitor cells, enriched CD34+ cells at 2 x l(f/m\ were cultured in IMDM 
supplemented with 10% FCS. The cultures were performed in the presence of two 
cytokine treatments with the addition of various concentrations (0 — 800 ng/ml) of 
MBL for 35 days. Cytokines added to group A were 50 ng/ml TPO, 25 ng/ml SCF, 
20 ng/ml IL-lp, 25 ng/ml IL-6 and 25 ng/ml IL-11. Cytokines added to group B were 
50 ng/ml TPO, 25 ng/ml SCF and 50 ng/ml FL. 
At day 0, the purity of enriched CD34+ cells was 91.6 士 1.65o/o (range 85.2 — 98.7%). 
The viability as determined by trypan blue dye exclusion assay were 93.4 土 1.13o/o 
(range 87.5 - 96.0%), 87.5 土 1.12o/o (range 82.2 一 90.4%), 78.3 士 1.53o/o (range 70.8 
—83.5%) and 73.5 土 1.18o/o (range 69.5 — 81.5%) at days 14，21, 28 and 35, 
respectively. No significant difference in cell viability was observed between 
treatments. The expansion results at days 14’ 21, 28 and 35 were summarized in 
Table 5.1 - 5.4. Total nucleated cells increased with the duration of culture. In both 
groups A and B, no significant difference was observed in the expansion of total 
nucleated cells with the addition of MBL (Figure 5.1). 
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Expansion of CD34+ Cells 
At day 14, the culture with 200 ng/ml MBL had the highest percentage of CD34+ 
cells among all the group A cultures (p < 0.05) (Table 5.1). However, no significant 
difference was observed in the absolute numbers of CD34+ cells. At days 21, 28 and 
35, there were no significant differences in the percentages and the yields of CD34+ 
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cells between cultures with MBL and the control in group A although a trend of 
better expansion was observed in cultures with 200 ng/ml MBL (Table 5.2 - Table 
5.4). 
In group B, the percentages of CD34+ cells in cultures with 200 ng/ml MBL were 
significantly higher than others at days 14，21, 28 and 35 (p < 0.05) (Table 5.1 — 5.4). 
The yields of these cells were also the highest in cultures with 200 ng/ml MBL at 
days 21, 28 and 35. The fold increase of CD34+ cells in culture with 200 ng/ml MBL 
at day 28 was significantly higher than that of the control (p < 0.05). In contrast, 
higher concentrations (400 and 800 ng/ml) of MBL decreased the expansion of these 
cells (Figure 5.2). At days 28 and 35，cultures with 800 ng/ml MBL showed 
significantly lower fold increases of CD34+ cells when compared to the control 
cultures (p < 0.05). The fold increases of CD34+ cells were the highest at day 28 
(Figure 5.2). Comparing two cytokine treatments, the yields of CD34+ cells in group 
B were significantly higher than those in group A at day 14, 28 and 35 (p < 0.05). 
Expansion ofCD34^CD38' Cells 
In group A, the percentage of CD34^CD38" cells was significantly higher in cultures 
with 200 ng/ml MBL when compared to the respective control cultures at days 14 
and 35 (p < 0.05) (Table 5.1 and Table 5.4). At days 21 and 28, no significant 
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difference in the percentage of these cells was observed among all the treatments 
(Table 5.2 and 5.3). Higher concentration of MBL again appeared to suppress the 
expansion of CD34+CD38- cells. The fold increases of CD34十CD38- cells in cultures 
with 800 ng/ml MBL were significantly lower than those of the control cultures at 
days 28 and 35 (p < 0.05) (Figure 5.3). The expansion of CD34+CD38- cells was the 
highest at day 14. 
In group B, the percentages and fold increases of CD34^CD38' cells in cultures with 
200 ng/ml MBL were superior to other cultures at all the time points (p < 0.05) 
(Table 5.1 - 5.4 and Figure 5.3 - 5.4). In addition, significantly higher percentages of 
these cells were observed in cultures with 100 ng/ml MBL when compared to the 
controls at days 14 and 28 (p < 0.05). Again, high concentrations of MBL appeared 
to suppress the expansion of CD34^CD38' cells with significant decreases observed 
in cultures with 400 ng/ml MBL at day 28 and 800 ng/ml MBL at days 28 and 35 (p 
< 0.05) (Figure 5.3). The cytokines in group B cultures supported more efficient 
expansion of these cells than those in group A (p < 0.05 at days 14, 21, 28 and 35). 
Expansion of Colony-Forming Unit 
In group A, the yields of total CFU (CFU-GM + BFU/CFU-E + CFU-GEMM) in 
cultures with 200 ng/ml MBL were significantly higher than the control cultures at 
days 28 and 35 (p < 0.05) (Figure 5.5). The yield of total CFU was also higher in 
culture with 100 ng/ml MBL at day 35 when compared to the control (p < 0.05). In 
group B, 200 ng/ml MBL supported higher yields of total CFU when compared to 
the controls at days 14, 28 and 35 (p < 0.05). The yield of total CFU in culture with 
800 ng/ml MBL was significantly lower than that of the control at day 35 (p < 0.05). 
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No significant differences were observed among two cytokine treatment groups and 
the expansion of total CFU was the highest at day 35. 
For the expansion of CFU-GM, 200 ng/ml MBL in group A enhanced the fold 
increase of CFU-GM at days 14, 28 and 35 (p < 0.05) (Figure 5.6 and Figure 5.7). At 
days 14, 21 and 28, 800 ng/ml MBL inhibited the expansion of CFU-GM (p < 0.05). 
At day 35, significantly higher yield of CFU-GM was also observed in culture with 
100 ng/ml MBL when compared to the control (p < 0.05). In group B, the cultures 
with 200 ng/ml MBL had the highest yield of CFU-GM at days 14，28 and 35 (p < 
0.05) (Table 5.1 — 5.4). Again, 800 ng/ml MBL inhibited the expansion at day 35 
(Figure 5.6). Similar to total CFU, no significant differences were observed between 
groups A and B and the expansion of CFU-GM was the highest at day 35. 
In group A, MBL appeared to have no effect on the erythroid lineage (Figure 5.8). 
The fold increases of BFU/CFU-E in group B were significantly higher than those in 
group A at day 14 and 21 (p < 0.05). In group B, 200 ng/ml MBL supported the 
highest yields of BFU/CFU-E at all the time points (p < 0.05) (Figure 5.7 and Figure 
5.8). The expansion of BFU/CFU-E was the highest at day 14 and the lowest at day 
35. 
For the early progenitors, no significant difference in the expansion of CFU-GEMM 
was observed in group A (Figure 5.9). In contrast, 200 ng/ml MBL supported the 
highest yields and fold increases of CFU-GEMM in group B at all the time points (p 
< 0.05) (Table 5.1 — 5.4, Figure 5.7 and Figure 5.9). Similarly to other CFU subsets, 
400 and 800 ng/ml MBL produced less CFU-GEMM than the controls (p < 0.05 at 
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day 14). The expansion of CFU-GEMM was significantly higher in group B when 
compared to those in group A at days 14, 21 and 28. In addition, the yields of CFU-
GEMM decreased with time. 
Considering the megakaryocytic lineage, MBL did not exert any effect on the 
expansion of CD61+CD41+ cells in both groups A and B (Table 5.1 - 5.4). No 
significant difference was found in the expansion of CFU-MK in both groups except 
at day 14 in group B. The fold increase of CFU-MK with 200 ng/ml MBL at day 14 
was the highest among all cultures in both groups A and B (p < 0.05) (Figure 5.10). 
5.1.2 Effects of Mannose-Binding Lectin on the Preservation of Early Stem 
and Progenitor Cells 
Total CFU 
To examine the effects of MBL on the preservation of hematopoietic stem and 
progenitor cells, MNC at 2 x lOVml or enriched CD34+ cells at 2 x l o V l were 
cultured in X-Vivo 10 without any cytokine supplement in the presence of 0 — 1,600 
ng/ml MBL for 35 days. For comparison, some cultures contained 40 ng/ml FL with 
or without 200 ng/ml MBL. High concentrations of MBL appeared to suppress the 
formation of total CFU at 400 — 1,600 ng/ml while 200 ng/ml MBL exerted similar 
effects as FL and FL+MBL200 (Figure 5.11). At day 14, significantly higher total 
CFU formations were also observed in MNC cultures with FL and FL+MBL200 
when compared to those of the control (p < 0.05). No significant difference was seen 
when 200 ng/ml MBL was compared to the control (Table 5.5). At days 21, 28 and 
35, the yields of total CFU in cultures with 200 ng/ml MBL, FL and FL+MBL200 
were higher than those of the respective control cultures (p < 0.05) (Table 5.6 — 5.8). 
72 
Significant lower yields of total CFU were observed in cultures with 800 and 1,600 
ng/ml MBL at days 14, 28 and 35 when compared to the control cultures. Among all 
time points, no significant difference was found when 200 ng/ml MBL was added to 
cultures with FL (Figure 5.11). 
In CD34+ cell cultures, 200 ng/ml MBL and FL+MBL200 produced higher yields of 
total CFU than the control at day 14 (p < 0.05). On the other hand, lower yields of 
total CFU were observed in cultures with 400 — 1,600 ng/ml MBL when compared to 
the control at day 14 (p < 0.05) (Table 5.5). At days 21, 28 and 35, similar significant 
results were observed in cultures with both MNC and CD34+ cells (Figure 5.11). 
CFU-GM 
In MNC cultures, FL and FL+MBL200 produced significantly higher yields of CFU-
GM than the respective controls at days 14 and 21 while 400 - 1,600 ng/ml MBL 
produced lower yields (Figure 5.12 and Table 5.5 — 5.6). At day 28, significantly 
higher yields of CFU-GM were observed in cultures with 100 ng/ml and 200 ng/ml 
MBL, FL and FL+MBL200 (p < 0.05). Again, high concentrations (800 and 1,600 
ng/ml) of MBL suppressed the expansion (Table 5.7). At day 35, 200 ng/ml MBL, 
FL and FL+MBL200 produced higher yields of CFU-GM than the control (p < 0.05) 
(Table 5.8). 
In CD34+ cell cultures, 200 ng/ml MBL and FL+MBL200 produced higher yields of 
CFU-GM than the control at day 14 while 400 — 1,600 ng/ml MBL suppressed the 
expansion (p < 0.05) (Figure 5.12 and Table 5.5). At day 21, more efficient 
expansion was observed in cultures with 200 ng/ml MBL, FL as well as 
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FL+MBL200 (p < 0.05) (Figure 5.12 and Table 5.6). No significant difference was 
observed at day 28 between cultures with MBL and the control (Table 5.7). Again, 
200 ng/ml MBL, FL and FL+MBL200 produced higher yields of CFU-GM than the 
control at day 35 while the yield in culture with 1,600 ng/ml MBL was lower (p < 
0.05) (Table 5.8). Moreover, the yields of CFU-GM in cultures with 200 ng/ml MBL 
and FL+MBL200 were significantly higher than that with FL alone (p < 0.05) 
(Figure 5.12). 
BFU/CFU-E 
In MNC cultures, the yields of BFU/CFU-E in cultures with FL and FL+MBL200 
were significantly higher than those of the respective control cultures at all time 
points (p < 0.05) (Figure 5.13). At days 28 and 35, 200 ng/ml MBL supported higher 
yields of BFU/CFU-E (p < 0.05) (Table 5.7 and Table 5.8). 
In cultures with CD34+ cells, similar effects of MBL and FL were seen (Figure 5.13). 
In addition, MBL at high concentrations (400 — 1,600 ng/ml) produced less 
BFU/CFU-E than the control cultures (Figure 5.13). 
CFU-GEMM 
For the early progenitors, 200 ng/ml MBL, FL and FL+MBL200 supported higher 
production of CFU-GEMM in MNC cultures (Figure 5.14). The yield of CFU-
GEMM in cultures with FL+MBL200 was significantly higher than that with FL 
alone at day 21 (p < 0.05) (Table 5.6). 
In CD34+ cell cultures, 200 ng/ml MBL was shown to support the highest yields of 
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CFU-GEMM (Figure 5.14). At day 14，100 and 200 ng/ml MBL, FL and 
FL+MBL200 produced more CFU-GEMM than the control (p < 0.05). Significant 
difference was also observed with the addition of 200 ng/ml MBL to the culture with 
FL (Table 5.5). At days 21 and 28, the yields of CFU-GEMM in cultures with 100 
and 200 ng/ml MBL, FL and FL+MBL were significantly higher than those of the 
control cultures (p < 0.05) (Table 5.6 and Table 5.7). At day 35, 200 ng/ml MBL, FL 
and FL+MBL200 supported significantly higher yields of CFU-GEMM than the 
control. The addition of 200 ng/ml MBL to the culture with FL significantly 
increased the yields of CFU-GEMM (p < 0.05) (Figure 5.14 and Table 5.8). 
5.1.3 Transplantation of Expanded Cells into NOD/SCID Mice 
Enriched CD34+ cells were cultured in IMDM + 10% FCS with TPO, SCF and FL in 
the presence or absence of 200 ng/ml MBL for 14 days. Expanded cells from nine 
CB samples were then transplanted into 50 NOD/SCID mice, 25 for each group. Five 
mice from each group died within 6 weeks of transplantation. In the group without 
MBL, 15 out of 19 mice showed engraftment of expanded human cells as analyzed 
by flow cytometry (Figure 5.15 — 5.18) and PGR analysis (Figure 5.19). The 
percentage of human CD45+ cells in the BM of transplanted mice was 16.7 士 5.47% 
(range 0.01 — 71.0%) (Figure 5.15 and Figure 5.19). The percentages of human 
CD45+ cells in the spleen (Figure 5.16) and PB (Figure 5.17) of mice were 2.97 土 
1.19% (range 0.00 一 12.9%) and 0.83 土 0.50o/o (range 0.00 — 6.70%), respectively 
(Figure 5.19). For those mice with more than 1% human CD45+ cells in the BM, the 
hematopoietic subsets were analyzed by flow cytometry (Figure 5.18). The 
percentages of human CD45+ subpopulations CD34+, CD33+, CD14+, CD19+ and 
CD61+ cells were 1.28 土 0.41o/o (range 0.05 - 3.14%), 30.1 土 6.50o/o (range 16.8 — 
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47.2%), 8.08 土 1.530/0 (range 4.91 — 12.3%), 12.3 土 2.51 (range 4.43 — 17.9%) and 
0,32 土 0.27O/O (range 0.00 - 1.40%), respectively. 
In the group of mice transplanted with MBL-expanded cells, 17 out of 19 mice 
showed engraftment of expanded human cells. The percentages of human CD45+ 
cells in the BM, spleen and PB of transplanted mice measured by flow cytometry 
were 11.4 土 4.39o/o (range 0.04 — 79.3%), 1.29 土 0.64o/o (range 0.00 — 6.60%) and 
0.73 士 0.29O/O (range 0.01 — 3.26%), respectively (Figure 5.19). The human CD45+ 
cells in BM consisted of 1.59 土 0.29o/o (range 0.44 — 3.20%) CD34+ cells, 24.2 土 
6.83% (range 13.3 — 51.1%) CD33+ cells, 7.60 士 2.60o/o (range 2.96 - 17.6%) CD14+ 
cells, 19.8 士 6.830/0 (range 0.00 — 42.14%) CD19+ cells and 0.30 土 0.23o/o (range 0.00 
一 1.18%) CD61+ cells (Figure 5.20), Paired t-test or Wilcoxon Sign Rank test， 
whichever suitable, was performed to compare the engrafting ability of cells 
expanded in both groups. No significant difference was observed. 
Section 5.2 Discussion 
The aim of this study was to elucidate the effects of a plant MBL on hematopoietic 
stem and progenitor cells. Several approaches were applied, including 1) ex vivo 
expansion of CB CD34+ cells, 2) preservation of primitive hematopoietic stem and 
progenitor cells and 3) transplantation of MBL-expanded cells into NOD/SCID mice. 
Two cytokine cocktails were selected for the expansion of megakaryocytic 
progenitors (group A containing TPO, IL-lp, IL-6 and IL-11) and early progenitor 
cells (group B containing TPO, SCF and FL). In general, there was a trend of 
superior expansion of megakaryocytic cells in group A, with up to 15.9% of 
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CD61+CD41+ cells at day 14. The early progenitor cells in terms of CD34^CD38' 
cells and CFU-GEMM were significantly higher in group B. 
MBL had no effect on the cell viability and expansion of nucleated cells and 
megakaryocytic lineage (CD61+CD41+ cells and CFU-MK) at all doses and time 
points. On the other hand, MBL at 200 ng/ml significantly increased the expansion of 
early progenitor cells including the populations of CD34+ cells, CD34^CD38' cells 
and CFU-GEMM up to 32.2-fold, 282-fold and 27.5-fold, respectively in the 
presence of three early-acting cytokines TPO, SCF and FL. However, increasing 
dosage of MBL to 400 and 800 ng/ml had inhibitory effects on the expansion. 
The ability of MBL on the preservation of early stem and progenitor cells was 
studied in a serum-free X-Vivo 10 medium without cytokine supplements for 35 
days. Using MNC and enriched CD34+ cells as the seeding populations, CFU of all 
lineages significantly decreased with the duration of culture. MBL at 0 — 200 ng/ml 
preserved the CFU at a dose-dependent manner but the effect declined with the 
increase in the concentration of MBL. The addition of FL at 40 ng/ml also 
significantly preserved these progenitors. Interestingly, MBL had a more tremendous 
effect than FL on the expansion of CFU-GEMM at days 14 and 35, and CFU-GM at 
day 35. The addition of MBL to cultures with FL, however, did not enhance the 
effect of FL. 
We further compared the engraftment capacity of progenitor cells expanded with 
group B cytokines for 14 days with and without MBL in sub-lethally irradiated 
NOD/SCID mice. Although the majority of transplanted mice showed engraftment of 
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human CD45+ cells and subsets in their BM, spleen and PB, the engraftment was not 
affected by the presence of MBL in the expansion. 
Our results appeared to agree with those of Colucci et al. (1999) who reported that 
flt-3 receptor-interacting lectin (FRIL) extracted from red kidney beans preserved 
CFU from CB MNC in X-Vivo 10 for one month without medium change. Kollet et 
al. (2000) then reported that CB CD34+ cells pre-incubated with FRIL alone could 
respond to cytokine stimulation and engrafted in NOD/SCID mice. They also 
reported that over 90% of cells after 13 days of incubation with FRIL were in the 
resting phase of the cell cycle. 
Our study demonstrated that MBL at 200 ng/ml had the ability to preserve early stem 
and progenitor cells in in vitro cultures but higher dosage appeared to have adverse 
effects. However, the mechanism of such action of this plant MBL is unclear. Human 
serum MBL has been shown to play an important role in immune defence, 
particularly during the phase of primary contact with microorganisms through its 
binding specificity to the repeating sugar arrays on microbial surfaces (Turner et al 
1998). In our study, the MBL purified from plant materials act differently from other 
cytokines such as FL which preserves early progenitors but concurrently promotes 
both proliferation and differentiation (Dooley et al 1997, Haylock et al 1997, 
Abkowitz et al 1998, Goff et al. 1998). One reason why we did not observe any 
effect of MBL on the NOD/SCID mouse transplantation was possibly because the 
experimental design was inadequate, considering that cultures at day 14 with or 
without MBL might contain su伍cient SCID-repopulating cells (SRC) for 
engraftment. In addition, a larger sample size and a longer duration post-transplant 
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might be required to demonstrate quantitative differences between the two trealmcnl 
groups. 
In conclusion, MBL at 200 ng/ml appeared to enhance the expansion and 
preservation of early hematopoietic stem and progenitors. Future investigations are 
needed to confirm the mechanism of this agent. If proven to be effective, MBL could 
be applied for the ex vivo expansion of hematopoietic stem and progenitor cells. 
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Table 5.1 - 5.4 Effects of Mannose-Binding Lectin on the Ex Vivo Expansion 
of Cord Blood CD34+ Cells at Day 14，21，28 and 35 
Enriched CD34+ cells at 2 x lO^ml were cultured in IMDM + 
10% FCS with two cytokine treatments plus various 
concentrations of MBL for 35 days. Tables (A) were cell 
products cultured with 50 ng/ml TPO, 25 ng/ml SCF, 20 ng/ml 
IL-lp, 25 ng/ml IL-6 and 20 ng/ml IL-11. Tables (B) were cell 
products cultured with 50 ng/ml TPO, 25 ng/ml SCF and 50 
ng/ml FL. MBL was added to each culture at 0, 50, 100, 200, 400 
and 800 ng/ml. Cells from 1ml of cultures at day 0 were 
harvested for analysis at days 14, 21, 28 and 35. Results were 
expressed as mean 士 S.E. n = 8, * p < 0.05 (higher than the 
control) and + p < 0.05 (lower than the control). 
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Table 5.1 Effects of Mannose-Binding Lectin on the Ex Vivo Expansion of 
Cord Blood CD34+ Cells at Day 14 
(A) 
Control MBL50 MBLIOO MBL200 MBL400 MBLSOO" 
TNC(x 10” 2.98±1.03 2.45 ± 0.40 1.80±0.30 1.89 ±0.26 2.39 ± 0.24 2.08±0.31 
CD34+Cells (o/o) 6.21 ± 1.34 5.77 ±0.89 5.67 ±0.97 8.10 ±0.88* 5.19 ±0.85 5.06 ±0.86 
CD34+Cells (X 105) 1.85 ±0.05 1.41 ±0.03 1.02±0.03 1.53 ±0.03 1.24±0.02 1.05±0.03 
CD34^CD38' Cells (%) 0.47 ±0.24 0.85 土 0.30 0.93 士 0.33 1.22 土 0.43 0.70 ±0.25 0.46 ±0.10 
CD34^ CD38- Cells (x 10^) 1.59±8.10 2.00 土0.73 1.73 ±6.60 2.14±9.50 1.45 ±5.60 0.65 ±3.50+ 
Total CFU (x 10"^ ) 4.89±0.76 4.54±0.82 3.99±0.83 6.46± 1.15 3.27±0.64 2.47 ± 0.56 
CFU-GM (x 10^) 3.93± 1.65 3.68 ±1.37 3.00± 1.16 5.44±3.65* 2.37± 1.77 1.67±1.05+ 
BFU/CFU-E (x 10^) 6.40 士 3.52 5.37 士 2.58 6.55 ± 1.70 6.65 ±3.73 5.81 ± 1.20 4.95 ±3.38 
CFU-GEMM (x 10^) 3.22 ± 1.17 3.28 ±2.45 3.37 ± 1.85 3.55 ±2.54 3.17 ±2.15 3.05 ±1.52 
CD61+CD41+Cells (o/o) 14.9±3.13 15.9 士 2.61 11.9±2.67 12.0±1.78 15.0 士 1.58 12.1 ±2.03 
CD61+CD41+Cells (X 105) 4.36 ± 1.54 3.69 ±1.01 2.30 ± 0.94 2.16 ±0.44 3.51 ±0.55 2.83 ±1.09 
CFU-MK ( X 1 0 6 ) 1 .32 ±0.55 1.65 ± 1.03 2 . 0 1 ±0.88 2 . 1 3 ± 0 . 8 5 1 . 8 8 ± 0 . 7 1 1.65 ±0.98 
(B) 
Control MBL50 MBLIOO MBL200 MBL400 MBL800~ 
TNC(x 10') 2.91 +0.35 2.97 + 0.32 2.98 + 0.38 2.82 ±0.37 2.79 ± 0.50 2.77 ±0.21 
CD34+Cells (o/o) 7.68 ±0.49 7.50 土 0.68 8.00 ± 0.57 8.76 ± 0.57* 7.32 ± 0.48 6.33 ± 0.44 
CD34+Cells (X 105) 2.28 ±0.36 2.21 ±0.30 2.37±0.35 2.47 ± 0.32 1.98±0.32 1.79±0.23 
CD34+CD38-Cells (o/o) 2.13±0.20 2.32±0.24 2.53 ± 0.27* 3.32 ± 0.19* 2.61±0.18 1.84±020 
CD34^ CD38- Cells (x 10^) 6.09± 0.88 6.88 ± 1.07 7.24 ± 1.02 9.43 ± 1.35* 6.75 ± 0.72 5.11 土 0.70 
Total CFU (x 10') 3.99±0.92 4.57± 1.23 5.81 ± 1.82 8.34 ± 2.12* 4.58 士 2.39 3.38 ±0.57 
CFU-GM (x 10^) 2 . 3 9 ± U 7 2.97 土 3.50 3.95 ± 4.50 6.08 ± 4.40* 3.04 ± 1.15 L87±0.88 
BFU/CFU-E (x 10^) 10.1 土 2.55 9.77±3.88 11.2±5.00 13.2±3.00* 9.98 ±3.20 9.50±5.21 
CFU-GEMM (x 10^) 5.90± 1.18 6.23 土 4.58 7.45 ± 1.64 9.42 ± 2.65* 5.44 ± 3.94 5.56 士 4.00 
CD61+CD41+Cells (o/o) 8.32 ±1.31 7.96 ±1.29 8.06 ±1.12 7.50 ±1.13 7.47 ±1.45 5.98 ±0.94 
CD61+CD41+Cells (X 105) 2.31 ±0.47 2.25 ± 0.42 2 . 27 ± 0.46 1.89 土 0 .36 1.63 ±0.30 1.64 ± 0 . 2 6 
CFU-MK (x 106) 2.85 ±0.87 3.06 ± 1.05 3.19 ±0.68 3.95 士 1.56 3.01 ±2.17 2.98 ± 0.99 
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Table 5.1 Effects of Mannose-Binding Lectin on the Ex Vivo Expansion of 
Cord Blood CD34+ Cells at Day 14 
(A) 
Control MBL50 MBLIOO MBL200 MBL400 MBLSOO" 
TNC ( X 10') 8.58 + 1.30 8.58 + 2.19 7.69 + 2.31 7.89 + 2.71 10.3 ±1.96 8.44 ±1.31 
CD34+Cells (o/o) 1.98 ±0.69 1.87 ±0.52 1.96 ±0.55 3.41 ±0.57 1.70 ±0.32 1.59 ±0.41 
CD34+Cells (X 105) 1.69 ±0.10 1.60 ±0.11 1.51 ±0.13 2.70 ±0.16 1.75 ±0.06 1.34 ±0.06 
CD34^CD38" Cells (%) 0.03 ±0.01 0.06 土 0.02 0.06 ±0.02 0.10 ±0.02 0.04 士 0.01 0.02 ±0.01 
CD34^ CD38" Cells (x 10^) 2.47 ±0.85 4.12 ± 1.24 3.13 ±0.45 5.02 ±1.19 3.73 ± 1.00 1.28 ±1.29 
Total CFU (X 104) 8.95 土 2.24 7.60± 1.32 7.23 ±2.08 9.13 ±3.00 7.84± 1.29 5.37±0.95 
CFU-GM (x 10^) 8.21±3.42 6.96±2.65 6.49±3.33 8.34 士 5.12 7.20±5.71 4.75±1.16+ 
BFU/CFU-E (x 10^) 5.40±2.34 4.20 士 1.16 5.18±2.20 5.60±2.11 4.54 士 1.65 4.30±0.85 
CFU-GEMM (x 10^) 2.00±0.98 2.18± 1.02 2.19± 1.07 2.28 ± 0.54 1.88 士 0.78 1.92±0.44 
CD61+CD41+Cells (o/o) 0.91 ±0.14 0.92 ±0.15 0.81 ±0.17 1.16 ±0.19 0.94 ±0.17 0.50 ±0.13 
CD61+CD41+Cells ( X 1 0 5 ) 2.77 ±1.16 2 . 1 5 ± 1 . 3 2 4 . 1 3 ± 1.46 5.85 ± 2 . 0 7 4 . 1 1 ± 1 . 4 5 2.15 ±0.76 
CFU-MK (X 10^) 9 . 4 5 ± 3 . 2 8 9.65 土 4.55 11.1 ± 5 . 2 1 13.0 士 2.55 7 . 54 土 1 .42 8 .84 ±2.52 
(B) 
Control MBL50 MBLIOO MBL200 MBL400 M B L 8 ^ 
TNC (X 1 0 , 6.12 ±0.34 5.75 ±0.39 5.46 + 0.40 5.52 + 0.60 5.02 + 0.46 5.47 ±0.31 
CD34+Cells (o/o) 4.89 ±0.44 4.81 ±0.30 5.03 ±0.38 6.09 ±0.35* 4.42 ±0.31 4.13 ±0.10 
CD34+Cells (X 105) 3.07±0.39 2.80±0.31 2.85 ±0.39 3.49 ±0.52* 2.27 ±0.32 2.27±1.63 
CD34+CD38-Cells (o/o) 1.15 ±0.15 1.54 ±0.22 1.56 ±0.15 2.29 ±0.14* 1.32 ±0.17 0.93 ±0.16 
CD34^ CD38- Cells (x 10^) 6.95 ±0.90 8.56 ± 1.03 8.42 ±1.00 12.5 士 1.29* 6.68 ±1.04 5.11 ±0.97 
Total CFU (x 10^) 4.77±0.39 4.06 ± 0.40 4.31 ±0.58 5.19±0.44 3.97±0.34 4.57±1.00 
CFU-GM (x 10^) 3.46 ±2.10 2.65 ±0.87 2.82 ±0.45 3.37 ±0.18 2.59 ± 1.12 3.26 ±1.19 
BFU/CFU-E (x 10^) 8.75±4.32 9.23 ± 1.79 9.88 ±3.28 11.5±2.98* 9.11±4.20 8.92±3.24 
CFU-GEMM (x 10') 4.32± 1.78 4.88 ±3.50 5.05 ±2.46 6.73 ±2.97* 4.73 ±2.85 4.20±3.50 
CD61+CD41+Cells (o/o) 1.48±0.26 1.36±0.3：3 1.34±0.31 1.45±0.33 1.24±0.31 1.23±034 
CD61+CD41+Cells (X 104) 9.39 ± 1 . 9 1 7.98 土 1.97 7.64 土 2.11 8 . 0 3 ± 2 . 2 1 6.04 土 1.51 7 .28 士 2 .28 
CFU-MK (x 105) 11.6±3.56 12.2±4.32 13.3 土 2.78 15.6±1.88 12.8±7.12 11.7±116 
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Table 5.1 Effects of Mannose-Binding Lectin on the Ex Vivo Expansion of 
Cord Blood CD34+ Cells at Day 14 
(A) 
Control MBL50 MBLIOO MBL200 MBL400 MBL800 
TNC(x 1 0 , 19.8 + 3.96 15.2±2.27 17.4±3.88 16.2±4.22 21.2±5.02 16.6±3.34 
CD34+Cells (o/o) 1.35 土 0.54 1.47 ±0.63 1.44 ±0.65 2.07 ±0.80 1.14 ±0.51 0.99 ± 0.48 
CD34+Cells (X 105) 2.67±0.22 2.24±0.14 2.50 ±0.25 3.35 ±0.34 2.41 士 0.26 1.65 ±0.16 
CD34+CD38-Cells (o/o) 0.21 ±0.13 0.23 土 0.15 0.16 ±0.07 0.20 ±0.12 0.23 ±0.12 0.13 ±0.09 
CD34+CD38-Cells(x 104) 7.05 ±4.81 5.14士3.44 4.20土 1.53 11.3 士4.01 14.9±5.27 7.54±2.67 
Total CFU (x 10^) 6.51 士 0.81 6.54±0.90 8.65 ±1.56 13.4±2.92* 8.82±2.45 4.13 ±0.80 
CFU-GM (x 10^) 5.90 ±0.98 5.88 ± 1.65 7.91 士 3.28 12.6 ±3.66* 8.16 土 1.49 3.56 ±1.33+ 
BFU/CFU-E (x 10^) 4.90 士 1.65 5.20±2.65 5.98± 1.49 6.11 ± 1.65 5.42± 1.65 4.38 ±1.42 
CFU-GEMM (x 10^) 1.18±0.16 1.39±0.88 1.42±0.59 1.66 士 0.55 1.17±0.46 1.28±0.99 
CD61+CD41+Cells (o/o) 0.59 ±0.15 0.43 ±0.07 0.43 土 0.09 1.20 土 1.30 2.54 ±0.15 2.51 ±0.12 
CD61+CD41+Cells (X 105) 1.82±0.26 1.08±0.71 0.85 土 1.27 2.10士 1.66 1.26±2.45 U2±1.45 
CFU-MK (X 105) 7.21 ±2.65 7.32 士 5.45 8.42 ± 1.24 8.55 土 2.60 7.11 士 2.45 6.98 ±3.22 
(B) 
Control MBL50 MBLIOO MBL200 MBL400 M B L 8 0 ~ 
TNC(x 10” 12.4±2.11 12.1 ±1.59 11.8± 1.48 11.4+ 1.64 11.0+ 1.35 10.6±0.98 
CD34+Cells (o/o) 3.84±(X45 4.39 ±0.30 4.44 ±0.39 5.48 ± 0.37* 3.75 ±0.32 3.17 ±0.29 
CD34+Cells (X 105) 4.58 ±0.68 5.23 ±0.69 5.32 ±0.80 6.24 ± 0.92* 4.29 ± 0.69 3.47 ±0.51 + 
CD34+CD38-Cells (o/o) 1.49±0.14 1.73±0.28 1.81 ± 0.18* 2.54 ± 0.16* 1.64±0.25 1.24 ±0.21 
CD34^ CD38- Cells (x 10^) 19.3±4.18 19.9±3.47 21.6±5.54 29.0±5.04* 18.1 ±0.36+ 14.4±3.42+ 
Total CFU (x 10^) 4.34±0.78 4.42±0.91 6.38±1.43 8.38 ± 1.56* 5.09 ±1.41 6.15±1.98 
CFU-GM (x 10^) 3.58±2.80 3.58 ±3.88 5.40 ±2.84 7.05 ±2.79* 4.27 ±2.17 5.36±3.29 
BFU/CFU-E (x 10^) 4.65± 1.88 5.32±3.73 6.73 士 3.22 8.42 ± 2.46* 5.14 ± 1.98 4.99±2.06 
CFU-GEMM (x 10') 2.94±0.95 3.05 ±1.17 3.11 ± 1.83 4.87 ± 1.23* 3.02 ± 2.27 2.96±1.65 
CD61+CD41+Cells (o/o) 0.45 ±0.09 0.50 ±0.14 0.47 ±0.17 0.53 ±0.13 0.52 ±0.18 0.32 ± 0 07 
C D 6 1 + C D 4 1 + C e l l s (X 1 0 4 ) 5 . 3 1 ± 1 . 5 8 5 . 5 9 ± 1 . 3 5 4 . 7 2 ± 1 . 2 7 5 . 1 9 ± 1 . 1 2 4 . 6 5 ± 1 . 0 1 3 . 4 8 ± 0 . 8 9 
CFU-MK (x 10^) 8.65 ±3.22 9.11 土 1.49 9.65 ± 3.78 9.99 ±5.85 8.99±2.71 8.74士1.36 
83 
Table 5.1 Effects of Mannose-Binding Lectin on the Ex Vivo Expansion of 
Cord Blood CD34+ Cells at Day 14 
(A) 
Control MBL50 MBLIOO MBL200 MBL400 M B L S i 
TNC(x 1 0 , 21.8 ±2.57 21.2+3.53 29.9 ±4.33 28.6 ±4.25 26.5 ±6.87 24.5 ± 2.25 
CD34+Cells (%) 0.24 ±0.13 0.25 士 0.13 0.28 ±0.14 0.39 ±0.18 0.09 土0.03 0.02 ±0.01 
CD34+Cells (X 105) 0.52±0.04 0.53 ±0.05 0.83 ±0.06 1.11 士 0.08 0.23 ± 0.02 0.49 ± 0.02 
CD34^CD38' Cells (%) 0.05 ±0.03 0.07 士 0.04 0.10 ±0.05 0.17 ±0.19* 0.04 土 0.02 0.02 土 0.01 
CD34+CD38-Cells (X 104) 0.84 土 4 . 2 2 1.14 土 5 . 3 0 2 .71 ± 13.8 4 . 2 6 ± 2 0 . 3 0 .81 土 2 . 3 7 0 . 23 ± 1.36+ 
Total CFU (x 10^) 13.4 土 1.54 10.6±2.01 21.6 士 4.83* 30.1 ± 6.73* 19.1 士 4.82 23.1 ±1.01 
CFU-GM (x 10^) 13.0±5.46 10.0 ± 5.16 21.0 ± 3.53* 29.5 ± 15.7* 18.7±5.16 22.7±3.09 
BFU/CFU-E (x 10^) 3.20± 1.49 4.81 ± 1.47 4.53 士2.58 4.99 士 1.69 3.38 士 1.99 3.11 ± 1.65 
CFU-GEMM (x 10^) 0.97±0.16 1.01±0.69 1.11 ± 1.05 1.24±0.50 0.95 士 0.45 0.88 土 0.23 
CD61+CD41+Cells (o/o) 0.05 ±0.01 0.06 ±0.01 0.12 ±0.04 0.51 ±0.14 0.07 ±0.02 0.27 ±0.13 
CD61+CD41+Cells (X 104) 1.40 ±0.50 1.22 ±0.14 1.79 ±0.53 1.91 ±0.19 1.15 ±0.03 0.99 ± 0.08 
CFU-MK (X 105) 5.65 ± 1.13 5.45 ±1.24 4.21 ± 1.60 6.00 ±1.88 5.4；2±1.62 5.12±1.32 
(B) 
Control MBL50 MBLIOO MBL200 MBL400 M B L 8 0 ~ 
TNC(x 10') 19.9+ 1.47 19.6+ 1.66 19.3 ±1.95 19.7 ±1.59 18.2 ±1.35 16.0 ±1.62 
CD34+Cells (o/o) 2.00 ±0.12 1.84 ±0.09 1.97 ±0.04 2.52 ±0.13* 1.84 ±0.14 1.48 ±0.08 
CD34+Cells (X 105) 4.49±0.65 4.08 ±0.58 4.19±0.66 4.71 士 0.58* 3.27 ± 0.59+ 2.41 ± 0.40+ 
CD34+CD38-Cells (o/o) 1.11 ±0.18 0.85 ±0.20 0.99 ±0.16 1.29 ±0.23* 0.98 ± 0.23 0.74 ±0.21 
CD34+CD38-Cells (X 104) 25.2±0.47 19.2±0.52 21.9±0.58 24.9±0.61* 18.1±0.54 12.2±0.36+ 
Total CFU (x 10^) 14.1±2.14 14.4 土 2.33 17.6 ±3.20 24.8 ±2.82* 16.8±3.88 9.09 ±0.94+ 
CFU-GM (x 10^) 13.7±5.98 13.9±4.96 17.0±6.83 24.1 ±8.68* 16.3± 8.42 8.70±1.19+ 
BFU/CFU-E (x 10^) 3.17± 1.54 3.85 ±1.49 4.01 土 1.73 4.99±2.41* 3.45±1.65 3.00±1.93 
CFU-GEMM (x 10^) 1.02±0.85 1.11± 0.25 1.55 ±0.46 2.46 土 0.98* 1.13±0.08 0.95 土 0.07 
CD61+CD41+Cells (o/o) 0.05 ±0.01 0.06 ±0.01 0.08 ±0.01 0.12 ±0.02 0.06 ±0.01 0.05 ± 0.02 
CD61+CD41+Cells (X 104) 1.07 士 0.29 1.36 ±0.36 0.30±0.38 2.37 ± 0.50 1.10±0.20 0.66 ± 0.23 
CFU-MK (x 10^) 3.56 ±1.94 4.22 ±2.87 6.78 ± 3.65 8.88 士 2.98 7.21 ±3.56 6.13 ±2.78 
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Figure 5.1 Effects of Mannose-Binding Lectin on the Ex Vivo Expansion of 
Total Nucleated Cells 
MBL had no effect on the fold increases of total nucleated cells with 
both cytokine treatments. (A) 一 50 ng/ml TPO, 25 ng/ml SCF, 20 
ng/ml IL-ip, 25 ng/ml IL-6 and 25 ng/ml IL-11. (B) - 50 ng/ml TPO, 
25 ng/ml SCF and 50 ng/ml FL. Results were expressed mean 士 S.E. 
n= 8 
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Figure 5.2 Effects of Mannose-Binding Lectin on the Ex Vivo Expansion of 
CD34+ Cells 
MBL supported more efficient expansion of CD34+ cells at 200 ng/ml 
while 800 ng/ml was found to suppress these cells. * and + represented 
that significant differences in the fold increases of CD34+ cells when 
compared to the control cultures (p < 0.05). Results were expressed 
mean 土 S.E. n= 8 
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Figure 5.3 Effects of Mannose-Binding Lectin on the Ex Vivo Expansion of 
CD34+CD38 Cells 
Similar to CD34+ cells, *significantly higher fold increases of 
CD34^CD38' cells were shown in cultures with 200 ng/ml MBL and 
^significantly lower fold increases were seen in cultures with 800 
ng/ml MBL when compared to control cultures (p < 0.05). Results 
were expressed mean 土 S.E. n= 8 
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Figure 5.4 Flow Cytometry Analysis of CD34+ Cells and CD34 CD38 Cells 
Expanded cells were harvested at days 14, 21, 28 and 35 for flow 
cytometry analysis. Cells expanded with 0 一 400 ng/ml MBL were 
stained with CD34-FITC and CD38-PE monoclonal antibodies (C — 
G) and their isotypic controls (B). Results showed that 200 ng/ml 
MBL enhanced higher percentage of CD34^CD38' cells after 14 days 
of culture (F). 
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Figure 5.5 Effects of Mannose-Binding Lectin on the Fold Increase of Total 
CFU after Ex Vivo Expansion 
Expanded cells were harvested for CFU assay at days 14, 21, 28 and 
35 of culture. MBL *increased the expansion of CFU at lower 
concentrations (100 — 200 ng/ml) but ""inhibited the expansion at 800 
ng/ml (p < 0.05) when compared to the control cultures. Results were 
expressed mean 土 S.E. n= 8 
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Figure 5.6 Effects of Mannose-Binding Lectin on the Fold Increase of CFU-
GM after Ex Vivo Expansion 
Fold Increases of CFU-GM in both groups A and B peaked at day 35. 
The fold increases were the highest in cultures with 200 ng/ml MBL 
(* p < 0.05). Again, 800 ng/ml MBL decreased the fold increases of 
CFU-GM when compared to the control p < 0.05). Results were 
expressed mean ± S.E. n二 8 
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Figure 5.7 CFU derived from MBL-Expanded Cells 
(A) CFU-GM, (B) BFU-E and (C) CFU-GEMM were derived from 
cells expanded with 50 ng/ml TPO, 25 ng/ml SCF, 50 ng/ml FL and 
200 ng/ml MBL for 35 days. 
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Figure 5.8 Effects of Mannose-Binding Lectin on the Fold Increase of 
BFU/CFU-E after Ex Vivo Expansion 
No significant difference was observed in fold increases of 
BFU/CFU-E in group A. The fold increases in cultures with 200 
ng/ml MBL were higher than those of the control in group B (* p < 
0.05). Results were expressed mean 土 S.E. 8 
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Figure 5.9 Effects of Mannose-Binding Lectin on the Fold Increase of CFU-
GEMM after Ex Vivo Expansion 
No significant difference was observed in fold increases of CFU-
GEMM in (A). In (B), *200 ng/ml MBL enhanced the expansion of 
CFU-GEMM while +400 and 800 ng/ml suppressed the expansion at 
day 14 (p < 0.05) when compared to the control cultures. Results were 
expressed mean 土 S.E. n= 8 
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Figure 5.10 Effects of Mannose-Binding Lectin on the Fold Increase of CFU-
MK after Ex Vivo Expansion 
The formation of CFU-MK decreased with duration of culture. No 
significant differences were found between treatments except the fold 
increase of CFU-MK which was higher with 200 ng/ml MBL than the 
control in group B (* p < 0.05). Results were expressed mean 土 S.E. 
n= 8 
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Table 5.5 一 5.8 Effects of Mannose-Binding Lectin on CFU Formation at 
Day 14，21，28 and 35 
(A) MNC at 2 X 10^/ml or (B) CD34+ cells at 2 x l o V l were 
cultured in X-Vivo 10 with 0 — 1,600 ng/ml MBL, 40 ng/ml FL 
or 40 ng/ml FL + 200 ng/ml MBL for 35 days. Results were 
presented as the mean number of CFU formed from 5 ml cultures 
at day 0 土 S.E. n = 8, * p < 0.05 (higher than the control) and + p 
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Figure 5.11 Effects of Mannose-Binding Lectin on CFU Formation 
CFU were preserved in the presence of 200 ng/ml MBL or FL (* p < 
0.05). However, the expansion of CFU decreased at higher 
concentrations of MBL (+ p < 0.05). Results were presented as the 
mean number of CFU formed from 5 ml cultures at day 0 士 S.E. n = 8 
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Figure 5.12 Effects of Mannose-Binding Lectin on CFU-GM 
Significantly higher expansion of CFU-GM was seen in cultures with 
MBL200, FL and FL+MBL when compared to the control (* p < 
0.05). CFU-GM formation in group A appeared to be suppressed by 
high concentrations (> 400 ng/ml) of MBL (+ p < 0.05). At day 35, 
MBL200 and FL+MBL supported more efficient expansion of CFU-
GM in CD34+ cell cultures than FL (# p < 0.05). n = 8 
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Figure 5.13 Effects of Mannose-Binding Lectin on BFU/CFU-E 
Significantly higher yields of BFU/CFU-E than the control were 
obtained in MBL200, FL40 and FL+MBL in both groups A and B (* 
p < 0.05). The yields of BFU/CFU-E decreased in MBL400, MBL800 
and MBL1600 (+ p < 0.05) in group B. n = 8 
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Figure 5.14 Effects of Mannose-Binding Lectin on CFU-GEMM 
MBL200, FL40 and FL+MBL supported higher yields of CFU-
GEMM after 35 days of culture than the control in both (A) and (B) 
cultures and MBLIOO also exerted this enhancing effect in (B) (* p < 
0.05). The yields of CFU-GEMM in MBL200 were significantly 
higher than those in FL40 f p < 0.05) but had no differences with 
those in FL+MBL. n = 8 
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Figure 5.15 Flow Cytometry Analysis of Bone Marrow Cells of Transplanted 
NOD/SCID Mice: Determination of Human CD45+ Cells 
The percentage of human CD45+ cells (FL-3) in the BM of 
transplanted mice was analyzed by flow cytometry. Dead cells, which 
were Pl-positive were gated out (B). The expression of CD45 (cy5) 
(D) was determined by comparing with the isotypic control (C). 
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Figure 5.16 Flow Cytometry Analysis of Human CD45+ Cells in the Spleen of 
Transplanted NOD/SCID Mice 
The percentage of human CD45+ cells in the spleen of transplanted 
mice was analyzed by flow cytometry. Dead cells, which were PI-
positive were gated out (B). The expression of CD45 (cy5) (D) was 
determined by comparing with the isotypic control (C). 
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Figure 5.17 Flow Cytometry Analysis of Human CD45+ Cells in Peripheral 
Blood of Transplanted NOD/SCID Mice 
The percentage of human CD45+ cells in the PB of transplanted mice 
was analyzed by flow cytometry. Dead cells, which were Pl-positive 
were gated out (B). The expression of CD45 (cy5) (D) was 
determined by comparing with the isotypic control (C). 
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Figure 5.18 Flow Cytometry Analysis of Bone Marrow Cells of Transplanted 
NOD/SCID Mice: Determination of Cell Subsets 
The expression (FL-1) of CD34 (A), CD33 (B), CD14 (C), CD19 (D) 
and CD61 (E) on human CD45+ cells (FL-3) in BM of NOD/SCID 
mice engrafted with enriched CB CD34+ cells cultured with TPO, 
SCF, FL in the presence of MBL for 14 days. 
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Figure 5.19 PCR Analysis of Human-Specific Alpha Satellite DNA in 
Chromosome 17 in Bone Marrow of NOD/SCID Mice 
Transplanted with Expanded Human Cells 
Genomic DNA was extracted from the BM of transplanted mice and 
subjected to PCR. Gel electrophoresis illustrated that positive 
expression of human-specific DNA were observed in all mice. Human 
CB cells and non-transplanted NOD/SCID mouse BM cells were 
served as positive and negative controls, respectively. Different 
percentages of human cells were mixed with mouse cells and a set of 
standards was set up. 1 — H2O, 2 — normal mouse BM cells, 3 — DNA 
size marker, 4 — 0.1% human DNA, 5 — 0.5% human DNA, 6 — 1.0% 
human DNA, 7 一 5.0% human DNA, 8 - 10% human DNA, 9 — 30% 
human DNA, 10 — 35% human DNA, 11 — 13: transplanted mouse 
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Figure 5.20 Engraftment of Expanded Human Cells in NOD/SCID Mice 
Enriched CD34+ cells expanded in the presence or absence of 200 
ng/ml MBL were infused into irradiated NOD/SCID mice. After 6 
weeks, the engraftment of human CD45+ cells in the bone marrow 
(BM), peripheral blood (PB) and spleen (Sp) were quantified by flow 
cytometry. Results were expressed as the percentage of viable cells, n 
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Figure 5.21 Subsets of Human Hematopoietic Cells in the Bone Marrow of 
Engrafted NOD/SCID Mice 
The engraftment of human stem and progenitor (CD34+), myeloid 
(CD33+, CD14+), lymphoid (CD19+) and megakaryocytic (CD61+) 
cells were detected in the BM of transplanted NOD/SCID mice after 6 
weeks of transplantation. Results were expressed as the percentage of 
human CD45+ cells, n = 5 for each group. 
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CHAPTER SIX 
OPTIMIZATION OF CULTURE DURATION，CULTURE 
MEDIA，AUTOLOGOUS PLASMA AND CYTOKINE 
COMBINATIONS FOR THE PRECLINICAL EX VIVO 
EXPANSION OF HEMATOPOIETIC STEM AND 
PROGENITOR CELLS 
Section 6.1 Results 
The effects of culture duration, media, serum supplements and cytokine 
combinations on the ex vivo expansion of hematopoietic stem and progenitor cells 
were investigated. Enriched CD34+ cells were cultured in four media, IMDM, X-
Vivo 10, QBSF-60 and StemSpan, in the presence of four cytokine combinations 
consisting of TPO, SCF, FL, G-CSF and IL-6 with or without autologous CB plasma 
for 12 days. In separate experiments, 50 ng/ml TPO and SCF were replaced by 100 
ng/ml in cultures with or without FL in QBSF-60. Selected groups of expanded cells 
were transplanted into NOD/SCID mice for the assessment of their engrafting ability. 
6.1.1 Kinetics of Expansion 
At day 0’ the purity of enriched CD34+ cells was 92.7 士 1.30o/o (range 87.3 — 98.3%) 
and the viability of CD34+ cells was 98.5 土 0.53o/o (range 97.0 — 100%). At days 8 
and 12, the viability of cultured cells as determined by trypan blue dye exclusion 
assay was 95.0 土 0.96% (range 92.0 — 99.0%) and 92.7 土 1.52 (range 82.5 — 99.0%), 
respectively. Total nucleated cells increased with duration of culture. The fold 
increases of total nucleated cells were significantly higher at day 12 of culture in all 
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treatments as compared to their respective cultures at day 8 (p < 0.05) (Figure 6.1). 
Although the percentages of CD34+ cells and CD34+CD38+ cells decreased with the 
duration of culture, a general increase in absolute numbers of these cells was seen at 
day 12 except in cultures with TSFG6 at which the yields of CD34+ cells and 
CD34+CD38- cells at day 12 appeared to be lower than those at day 8 (Table 6.1). 
The fold increases of CD34+ cells in IMDM with TSF6; X-Vivo 10 with TSF and 
TSFG; QBSF-60 with TSF, TSFG and TSF6; and StemSpan with TSF and TSFG at 
day 12 were significantly higher than their respective cultures at day 8 while the fold 
increase of CD34+ cells in IMDM and StemSpan with TSFG6 at day 12 was 
significantly lower than that at day 8 (p < 0.05) (Figure 6.2). In addition, the fold 
increases of CD34^CD38' cells in cultures with TSF, TSFG and TSF6 at day 12 were 
higher than those at day 8 (p < 0.05 for IMDM with TSF, TSFG and TSF6; X-Vivo 
10 with TSF and TSF6; QBSF-60 with TSF, TSFG and TSF6; and StemSpan with 
TSFG and TSF6). Similar to CD34+ cells, the fold increases ofCD34^CD38" cells at 
day 12 were lower than those at day 8 in cultures with TSFG6 (p < 0.05 for X-Vivo 
10 and QBSF-60) (Figure 6.3). 
The colony-forming capacities of total CFU (CFU-GM + BFU/CFU-E + CFU-
GEMM) and CFU-GM were higher at day 12 as compared to day 8 (Table 6.2). 
However, the trend on BFU/CFU-E was mixed, being higher at day 12 in some 
cultures and at day 8 in others. The multipotent CFU-GEMM were significantly 
higher at day 12 (p < 0.05) in all cultures except those in IMDM, X-Vivo 10 and 
QBSF-60 with cytokine treatment TSF; in all media with TSF6; and in X-Vivo 10 
with TSFG6 where significant differences were not demonstrated. 
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CD61+CD41+ cells were significantly higher at day 12 comparing to day 8 results (p 
< 0.05), except in cultures with TSFG6 in four media at which only a trend was 
indicated (Figure 6.4). The numbers of CFU-MK were consistently higher in all 
cultures at day 12 when compared with those at day 8 (p < 0.05 for all media and 
treatments except in culture with TSFG6 in X-Vivo 10) (Figure 6.5 and 6.6). 
Considering the superior expansion of hematopoietic progenitors and subsets at day 
12 when compared to those at day 8, we decided to present day 12 results in the 
following experiments to elucidate the effects of different media and growth factors 
on the ex vivo expansion of CB hematopoietic stem and progenitor cells (Section 
6.1.2-6.1.7, Table 6.3 - 6.6, Figure 6.7 - 6.24). 
6.1.2 Assessment of Culture Media 
Four media, IMDM + 10% FCS, X-Vivo 10, QBSF-60 and StemSpan were studied 
in the presence of four cytokine combinations. The results were summarized in Table 
6.3. After 12 days of culture, the expansion of total nucleated cells was generally 
more efficient in cultures with StemSpan serum-free medium. The fold increases of 
total nucleated cells were significantly higher in StemSpan when compared to IMDM 
(P < 0.05 for TSF, TSFG and TSF6), X-Vivo 10 (p < 0.05 for all treatments) and 
QBSF-60 (p < 0.05 for TSFG) (Figure 6.7). 
Our results showed that QBSF-60 supported the highest expansion of both CD34+ 
cells and CD34^CD38" cells (Table 6.3). Significantly higher percentages of both 
CD34十 and CD34^CD38' cells were observed in QBSF-60 cultures when compared 
to those in IMDM, X-Vivo 10 and StemSpan (p < 0.05). QBSF-60 enhanced 
significantly higher yields and fold increases of these cells than other media (p < 
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0.05), except StemSpan with cytokine treatments TSF and TSFG, at which a trend 
was shown (Table 6.3 and Figure 6.8). 
The total colony-forming capacity appeared to be superior in QBSF-60 and 
StemSpan cultures when compared to IMDM (vs QBSF-60, p < 0.05 for cytokine 
treatments TSF, TSFG and TSF6; vs StemSpan, p < 0.05 for TSFG) and X-Vivo 10 
(P < 0.05 for all treatments) (Figure 6.9). The fold increases of CFU-GM in QBSF-
60 were higher than those in other three media (p < 0.05 for X-Vivo 10 with TSF, 
TSFG and TSF6; and StemSpan with TSF6) while the fold increase of CFU-GM in 
culture in StemSpan with TSF6 was significantly higher than that in X-Vivo 10 (p < 
0.05) (Figure 6.9). QBSF-60 also supported higher fold increases of BFU/CFU-E 
when compared to IMDM (p < 0.05 for TSF6), X-Vivo 10 (p < 0.05 TSF, TSF6 and 
TSFG6) and StemSpan (p < 0.05 for TSF6) while StemSpan produced higher fold 
increase of BFU/CFU-E than IMDM with cytokine treatment TSF (p < 0.05) (Figure 
6.9). Furthermore, the fold increases of multipotent CFU-GEMM were higher in 
QBSF-60 and StemSpan, particularly in the former medium (Figure 6.9). The fold 
increases of CFU-GEMM in StemSpan cultures were significantly higher than 
IMDM (p < 0,05 for TSF6) and X-Vivo 10 (p < 0.05 for TSFG, TSF6 and TSFG6). 
QBSF-60 produced the highest yield of CFU-GEMM when compared to cultures in 
IMDM (p < 0.05 for all treatments), X-Vivo 10 (p < 0.05 for all treatments) and 
StemSpan (p < 0.05 for TSFG, TSF6 and TSFG6) (Table 6.3). The yields of CFU-
GEMM in QBSF-60 were 119 - 437%, 196 — 2386% and 63 — 176% of those in 
IMDM, X-Vivo 10 and StemSpan, respectively. 
Considering the megakaryocytic lineage, the expansion appeared to be the most 
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effective in X-Vivo 10 (Table 6.3 and Figure 6.10). X-Vivo 10 produced the highest 
percentage of CD61+41+ cells in all cytokine treatments (Figure 6.10), and higher 
yield of these cells when compared to IMDM (p < 0.05 for all treatments), QBSF-60 
(P < 0.05 for TSFG, TSF6 and TSFG6) and StemSpan (p < 0.05 for TSFG, TSF6 and 
TSFG6) (Table 6.3). Similar trends were observed in the expansion of CFU-MK. The 
fold increases of CFU-MK in X-Vivo 10 cultures were significantly higher than 
those in IMDM (p < 0.05 for all treatments), QBSF-60 (p < 0.05 for TSFG, TSF6 
and TSFG6) and StemSpan (p < 0.05 for all treatments) (Figure 6.10). The yields of 
CFU-MK in X-Vivo 10 with different cytokine treatments were 125 - 198% of those 
in the other three media (Table 6.3). 
6.1.3 Effects of Autologous Cord Blood Plasma 
Enriched CD34+ cells were cultured in IMDM containing either 10% FCS or 10% 
autologous CB plasma, or in X-Vivo 10, QBSF-60 and StemSpan with or without 
autologous plasma in the presence of four cytokine treatments. Significant increases 
in total nucleated cells were observed in cultures containing autologous plasma in X-
Vivo 10, QBSF-60 and StemSpan (p < 0.05 for all treatments except in QBSF-60 and 
StemSpan with cytokine treatment TSFG) (Table 6.4). In contrast, no significant 
difference was observed in IMDM containing FCS or autologous plasma except in 
TSF where a significant increase was demonstrated in the presence of autologous 
plasma. 
Our results demonstrated that no significant differences were observed in the 
expansion of GD34+ cells when FCS was replaced by autologous plasma in IMDM 
cultures (Figure 6.11). However, the addition of autologous plasma to X-Vivo 10 (p 
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< 0.05 for all treatments), QBSF-60 (p < 0.05 for TSF, TSFG and TSFG6) and 
StemSpan (p < 0.05 for all treatments) serum-free media decreased both the 
percentages and the yields of CD34+ cells substantially (Figure 6.11). The fold 
increases of CD34+ cells in cultures with autologous plasma were 41.4 一 75.8%, 23.7 
—43.1% and 35.9 — 47.5% of those without plasma in X-Vivo 10, QBSF-60 and 
StemSpan, respectively. Similar to CD34+ cells, the expansion efficiency of 
CD34+CD38- cells were not different in the presence of FCS or autologous plasma in 
IMDM cultures (Figure 6.12). The percentages and the yields of CD34+CD38- cells 
decreased drastically when autologous plasma was added to cultures in the three 
serum-free media (p < 0.05) (Figure 6.12). The fold increases of these cells in X-
Vivo 10, QBSF-60 and StemSpan with autologous plasma were only 2.02 — 20.6%, 
12.7 - 20.4% and 3.37 — 11.0% of those in their respective cultures without 
autologous plasma. 
No significant difference was found in the expansion of total CFU and specific 
lineages of CFU in the presence of FCS or autologous plasma in IMDM (Table 6.5). 
In serum-free media, there was also no significant difference in the expansion of total 
CFU in the presence or absence of autologous plasma (Table 6.5). The addition of 
autologous plasma to the three serum-free media enhanced the expansion of CFU-
GM and BFU/CFU-E. The expansion of CFU-GM and BFU/CFU-E were 
significantly more efficient in the presence of autologous plasma in X-Vivo 10 (p < 
0.05 for all treatments), QBSF-60 (p < 0.05 for all treatments) and StemSpan (p < 
0.05 for TSF and TSFG6) (Table 6.5). On the other hand, the fold increases of CFU-
GEMM dropped in a dramatic manner when autologous plasma was added to 
cultures in X-Vivo 10 (p < 0.05 for all treatments), QBSF-60 (p < 0.05 for all 
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treatments) and StemSpan (p < 0.05 for TSF, TSFG and TSFG6) (Table 6.5). The 
yields of CFU-GEMM in cultures with autologous plasma were 59.2 — 87.8%, 44.9 — 
78.3% and 48.3 - 59.8% of those without plasma in X-Vivo 10, QBSF-60 and 
StemSpan, respectively. 
The yields of megakaryocytic CD61+CD41+ cells were reduced significantly by the 
addition of autologous plasma in X-Vivo 10, QBSF-60 and StemSpan (p < 0.05 for 
all treatments except StemSpan with TSFG) (Figure 6.13). No significant differences 
were demonstrated in cultures in IMDM with FCS or autologous plasma (Figure 
6.13). The fold increases of CFU-MK were also decreased when autologous plasma 
was added to the three serum-free media (p < 0.05 for all treatments except 
StemSpan with TSFG) (Figure 6.14). The yields of CFU-MK in cultures with 
autologous plasma were 85.0 — 96.0%, 84.9 — 96.0% and 80.9 — 92.7% of those 
without plasma in X-Vivo 10, QBSF-60 and StemSpan, respectively. 
6.1.4 Effects of Granulocyte-Colony Stimulating Factor 
In order to study the effects of G-CSF on the expansion of CB CD34+ cells, enriched 
CD34+ cells were cultured in four media, IMDM + 10% FCS, X-Vivo 10, QBSF-60 
and StemSpan, in the presence of TSF or TSF6 with or without G-CSF (Table 6.3). 
In all media, G-CSF increased total nucleated cells to 136 — 273% (p < 0.01) (Figure 
6.15) but decreased the percentage of CD34+ cells to 44.0 - 71.0% (p < 0.05) after 12 
days of culture (Table 6.3). As a result, there was no significant difference in the 
absolute number of CD34+ in the presence or absence of G-CSF except cultures in 
X-Vivo 10 with TSF, at which G-CSF significantly increased the yield of CD34+ 
cells (p < 0.01) (Figure 6.16). Moreover, the percentages of CD34^CD38" cells in 
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cultures with TSFG and TSFG6 dropped significantly to 43.0 — 60.6% of those in 
cultures with TSF (p < 0.05 for X-Vivo 10, QBSF-60 and StemSpan) and 39.6 一 
68.4% of those with TSF6 (p < 0.05 for IMDM, X-Vivo 10 and QBSF-60), 
respectively (Table 6.3). The significant decreases in the fold increases of 
CD34+CD38- cells were also observed in X-Vivo 10 and StemSpan with TSF6 (p < 
0.05) (Figure 6.16). 
G-CSF appeared to enhance the expansion of CFU in all cultures (Table 6.3 and 
Figure 6.17). In cultures with TSF, total CFU, CFU-GM, BFU/CFU-E and CFU-
GEMM were significantly elevated when G-CSF was added (p < 0.05). Similar 
results were obtained in cultures with TSF6, but significant increases were only 
observed in total CFU in cultures in StemSpan; CFU-GM in IMDM and QBSF-60; 
and CFU-GEMM in IMDM, QBSF-60 and StemSpan (p < 0.05). 
Our results demonstrated that the addition of G-CSF to cultures with TSF did not 
change the yields of CD61+CD41+ cells in all media (Table 6.3), although the 
percentages of these cells declined (p < 0.05 for IMDM, QBSF-60 and StemSpan) 
(Figure 6.18). The yields of CD61+CD41+ cells in cultures with TSFG6 decreased to 
42.5 - 70.7% of those with TSF6 (Table 6.3). However, G-CSF enhanced the 
formation of CFU-MK to 139 — 218% (p < 0.05 for all treatments except X-Vivo 10 
with TSF6) (Table 6.3 and Figure 6.18). 
6.1.5 Effects of Interleiikm-6 
Effects of IL-6 were studied in the four media with either TSF or TSFG (Table 6.3). 
IL-6 appeared to enhance the expansion of total nucleated cells. Significant increases 
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were observed in cultures with TSF in all media (p < 0.05), a trend was demonstrated 
in cultures with TSFG or TSFG6 (Figure 6.15). The presence of IL-6 increased the 
percentages (p < 0.05 for X-Vivo 10 with TSFG) and the yields (p < 0.01 for IMDM 
with TSF, QBSF-60 with TSF and TSFG) of CD34+ cells (Table 6.3 and Figure 
6.16). IL-6 affected the yields of CD34+CD38- cells in a similar fashion (p < 0.05 for 
QBSF-60 with TSF). 
The yields of total CFU were higher in all cultures with TSF6 when compared to 
ones with TSF (p < 0.05) (Table 6.3). The fold increases of total CFU in cultures 
with TSF6 were 150 — 183% of those in cultures with TSF (Figure 6.17). However, 
there was no significant difference in between TSFG and TSFG6 in the yields of 
CFU. The addition of IL-6 enhanced the expansion of CFU-GM (p < 0.05 for IMDM 
with TSF and QBSF-60 with TSFG), BFU/CFU-E (p < 0.05 for IMDM with TSF, X-
Vivo 10 with TSFG and QBSF-60 with TSF) and CFU-GEMM (p < 0.05 for IMDM 
and QBSF-60 with TSF). 
IL-6 did not consistently increase the expansion of CD61+CD41+ cells. Significant 
increases were only observed in IMDM and QBSF-60 with TSF (p < 0.05) (Figure 
6.18). IL-6 enhanced the formation of CFU-MK in all media. Significant increases 
were observed in cultures with TSFG (p < 0.05) (Figure 6.18). The yields of CFU-
MK in cultures with IL-6 were 132 - 169% as compared to cultures without IL-6. 
6.1.6 Effects of Increased Dosage of Thrombopoietin and Stem Cell Factor 
In the attempt to optimize the working concentration of TPO and SCF in the specific 
serum-free medium, the effects of two dosage (50 ng/ml and 100 ng/ml) of TPO and 
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SCF on the expansion of eight independent CB samples were studied in cultures with 
QBSF-60 in the presence of TPO, SCF, G-CSF, with or without FL. After dosage 
increment of TPO and SCF, the fold increase of total nucleated cells were elevated, 
together with the increases in the percentage of CD34+ cells (p < 0.01 for cytokine 
treatment TSFG). The yields and fold increases of CD34+ cells were also elevated in 
both cytokine treatments TSG and TSFG. Similar results for CD34^CD38' cells were 
observed (Table 6.6 and Figure 6.19). 
When 50 ng/ml TPO and SCF were replaced by 100 ng/ml TPO and SCF, all CFU 
formation including CFU-GM, BFU/CFU-E and CFU-GEMM elevated significantly 
in TSG (p < 0.05). In TSFG, significantly higher expansion was only observed in 
BFU/CFU-E (p < 0.05) (Table 6.6 and Figure 6.20). 
For the megakaryocytic lineage, the percentage and yield of CD61+CD41+ cells in 
cultures with 100 ng/ml TPO and SCF were higher than those with 50 ng/ml TPO 
and SCF (p < 0.01 for TSG) (Table 6.6). Moreover, the expansion of CFU-MK was 
higher in cultures with 100 ng/ml TPO and SCF when compared to cultures with 50 
ng/ml TPO and SCF (p < 0.05 for TSFG) (Table 6.6 and Figure 6.21). 
6.1.7 Effects of FIt-3 Ligand 
Enriched CD34" cells from eight CB samples were cultured in QBSF-60 in the 
presence of 50 ng/ml or 100 ng/ml TPO and SCF, 40 ng/ml G-CSF, with or without 
80 ng/ml FL to investigate the effects of FL on the e.v vivo expansion of CB CD34+ 
cells. The addition of FL to cultures containing both dosages of TPO and SCF, TSG 
and TSGIOO, significantly enhanced the expansion of total nucleated cells (p < 0.01) 
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(Table 6.6 and Figure 6.19). The fold increases of total nucleated cells in cultures 
with TSFG and TSFGIOO were up to 173% of those in cultures with TSG and 
TSGIOO. 
Both the percentage and the yield of CD34+ cells elevated with the addition of FL to 
the cultures (p < 0.01) (Table 6.6 and Figure 6.19). The fold increase of CD34+ cells 
were increased to 392% and 361% in cultures with TSFG and TSFGIOO, 
respectively. Adding FL also led to significant increases of the percentage and the 
yield of early CD34+CD38- cells (p < 0.05) (Table 6.6 and Figure 6.19). The fold 
increases of CD34^CD38" cells were increased to 264 - 273% when cultures were 
supplemented with FL. 
FL enhanced the expansion of all lineages of CFU (Table 6.6 and Figure 6.20). 
Significant increases of total CFU, CFU-GM, BFU/CFU-E and CFU-GEMM were 
illustrated in all cultures with FL (p < 0.01). 
However, no significant difference was observed in the yields of CD61+CD41+ cells 
in all cultures with or without FL although the percentages of these cells were 
significantly higher in TSFG and TSFGIOO when compared to TSG and TSFG, 
respectively (Table 6.6). In contrast, the expansion of CFU-MK was better when FL 
was added to cultures (p < 0.01) (Table 6.6 and Figure 6.21). 
6.1.8 Transplantation of Expanded Cells into NOD/SCID Mice 
The engraftment capacity of expanded cells in the NOD/SCID mouse model was 
investigated. Cryopreserved CB CD34+ cells were cultured in QBSF-60 medium 
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with TSG or TSFG for 12 days. Expanded cells from five CB cultures with each 
cytokine treatment were transplanted into 16 mice. In the TSG group, 13 mice 
remained alive after 6 weeks of transplantation and 11 of them showed engraftment 
of human cells. Flow cytometry and PGR were performed for the analysis. The 
percentages of human CD45+ cells in the BM, spleen and PB of these mice as 
measured by flow cytometry were 8.13 士 4.80o/o (range 0.01 — 52.6%), 1.77 土 0.21 
(range 1.47 — 2.17%) and 1.87 士 1.29o/o (range 0.54 — 4.45%), respectively (Figure 
6.22). In PGR analysis, all of these mice showed positive results, indicating that their 
BM contained cells with human-specific alpha-satellite DNA. The subsets of human 
hematopoietic cells were also detected in the BM of transplanted mice which 
contained more than 1% human CD45+ cells. The human CD45+ cells were consisted 
of 9.64 士 2.840/0 (range 4.82 — 14.6%) CD34+ cells, 21.9 土 0.95o/o (range 20.3 一 
23.6%) CD33+ cells，11.2 士 1.58o/o (range 8.97 — 14.2%) CD14+ cells, 24.9 土 8.02o/o 
(range 9.64 - 36.8%) CD19+ cells and 0.71 士 0.35o/o (range 0.02 — 1.13%) CD61+ 
cells (Figure 6.23). 
In the TSFG group, 12 mice remained alive for 6 weeks after transplantation and 
engraftment was observed in all of them. The percentages of human CD45+ cells in 
the BM, spleen and PB of these mice as measured by flow cytometry were 11.0 士 
3.950/0 (range 0.19 - 35.9%), 7.57 土 1.26 (range 5.25 — 9.57%) and 1.59 土 0.34% 
(range 1.10 — 2.25%), respectively (Figure 6.22). All of these mice demonstrated 
positive results in PGR analysis. In the BM of these mice, the subpopulations of 
human CD45+ cells were consisted of 9.63 土 4.30o/o (range 4.10 - 18.1%) CD34+ 
cells, 22.8 土 6.25% (range 10.7 — 31.5%) CD33+ cells, 8.87 土 2.48o/o (range 4.18 一 
12.6%) CD14+ cells, 28.7 土 15.9o/o (range 12.2 一 60.5%) CD19+ cells and 0.66 土 
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0.12% (range 0.51 — 0.89%) CD61+ cells (Figure 6.23). Although the mean levels of 
human CD45+ cell percentage engrafted in the BM of mice transplanted with TSFG-
expanded cells were higher than those with TSG-expanded cells, the percentages of 
CD45+ cells as well as the subsets were not statistically different by performing 
Wilcoxon Sign Rank test comparison (p = 0.0757). On the other hand, the percentage 
of human CD45+ cells in the spleen of mice transplanted with TSFG-expanded cells 
was significantly higher than that with TSG-expanded cells (p = 0.0161). 
Section 6.2 Discussion 
This study on the optimization of culture conditions for the expansion was conducted 
to establish a clinically applicable protocol for the ex vivo expansion of CB 
hematopoietic stem and progenitor cells. The expansion of CB CD34+ cells to 
different lineages of hematopoietic cells was systematically assessed with various 
parameters such as culture duration, serum-free media, autologous supplements and 
cytokines. 
The quality and quantity of cell products from ex vivo expansion cultures largely 
depends on the balance between the proliferative and maturation activities of seeded 
CD34+ cells, which are affected by the duration of culture. A prolonged duration of 
culture increases cost, the risk of contamination and the exhaustion of early 
multipotent progenitors. Most clinical expansions were performed within the period 
of seven to twelve days (Bertolini et al. 1997a, Kogler et al 1999, Paquette et al. 
2000, Stiff et al. 2000). In this study, the yields of most progenitor cell populations, 
in particular those of megakaryocytic progenitors, were shown to be higher at day 12 
when compared to those at day 8. More significantly, the early progenitors as 
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identified by the CD34+CD38- cells and CFU-GEMM at day 12 were either higher or 
similar to their respective cultures at day 8. Mobest et al. (1999) and Bhatia et al. 
(1997b) reported that transplantation of cell products from expansion of over four 
and nine days resulted in the failure of stem cell engraftment in NOD/SCID mice, 
respectively. However, using the optimized media/cytokines and culture duration of 
12 days, we obtained stable engraftments and human cell hematopoietic 
reconstitution in the NOD/SCID mouse transplantation model. 
Traditionally, FCS was used in most expansion protocols. However, in order to avoid 
the risk of allergic reagents, viral contamination, variation between batches and 
regulatory issues of FCS (Sandstrom et al. 1996, Kogler et al. 1998), serum-deprived 
medium would be preferably used in clinical expansion. A number of serum-free 
media have been developed over the last few years. Several studies demonstrated that 
serum-free medium could support better growth for hematopoietic cells (Sandstrom 
et al 1996, Kogler et al. 1998，Lefebvre et al. 1999, Mobest et al 1999, Qiu et al. 
1999，van den Oudenrijn et al. 2001). Three commercially available serum-free 
media were assessed in this study, in comparison with serum-containing IMDM. 
Autologous plasma has been used in some clinical expansion as an alternative 
nutrient supplement for replacing FCS (Brugger et al. 1995, Alcom et al. 1996, 
Bertolini et al 1997b, Kogler et al. 1999). If proven to be suitable，CB plasma can be 
obtained during the initial processing procedure of volume reduction and banked 
together with the CB unit. 
Our results demonstrated that IMDM with 10% FCS was not superior to other serum-
free media on the expansion of CB CD34+ cells. In the serum free media, the 
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addition of CB plasma enhanced the expansion of more mature progenitors, giving 
higher yields of CFU-GM and BFU/CFU-E at the expense of primitive CD34^CD38' 
cells and CFU-GEMM. Our results are in agreement with previous studies that CB 
plasma promoted differentiation of stem cells into myeloid and erythroid cells 
(Bertolini et al 1994, Ruggieri et al 1994). These data suggested that some factors 
in CB plasma might promote maturation and differentiation of hematopoietic cells 
and hence, reduce the expansion of multipotent CFU-GEMM. 
It is of great importance to obtain a serum-free medium which promotes the large-
scale ex vivo expansion for clinical use. In this study, QBSF-60 and to a lesser degree 
StemSpan were shown to support high yields of early progenitors as well as 
committed myeloid and erythroid cells. Qiu et al (1999) showed that QBSF-60 with 
a simple cytokine combination containing TPO, SCF and FL supported simultaneous 
expansion of various CB hematopoietic cell compartments. Almeida-Porada et al. 
(2000) also demonstrated hematopoietic engraftment in the human-to-sheep 
xenograft model after expansion in QBSF-60. Taken together, the data confirmed that 
QBSF-60 might be a good choice of serum-free medium for the expansion of CB 
CD34+ cells in a clinical setting. 
Interestingly, the expansion of megakaryocytic progenitors was consistently higher in 
X-Vivo 10. X-Vivo 10 has been used clinically in the expansion of CB (Kogler et al. 
1999) and mobilized PB hematopoietic stem and progenitor cells (Williams et al. 
1996, Bertolini et al 1997b). van den Oudenrijn et al. (2001) reported that StemSpan 
supported better expansion of CD41+ cells than IMDM with 10% human AB plasma 
or CellGro SCGM which was another serum-free medium. These reports reinforced 
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the observation that different medium might support the expansion of different 
lineages of hematopoietic cells. In our experimental conditions, X-Vivo 10 appeared 
to be the most suitable medium for the expansion of megakaryocytic progenitors 
with CD61+CD41+ cells and CFU-MK expansion up to 2.79 x 10^ cells per 2 x 10^ 
seeded CD34+ cells and 684-fold, respectively. 
The combination of three early-acting cytokines, TPO, SCF and FL, has been used in 
many culture systems using various culture media for both pre-clinical (Briddell et 
a/. 1997, Luens et al. 1998, Williams et al. 1998, Mobest et al 1999, Murray et al 
1999, Kobari et al. 2000, Kratz-Albers et al. 2000, Lefebvre et al. 2000, Lewis et al 
2000, Shih et al 2000, Xu et al. 2001) and clinical (Bertolini et al 1997b, Kogler et 
al. 1999, McNiece et al. 2000b, Paquette et al. 2000, Stiffen al 2000) studies with or 
without other cytokines. This combination was shown to have an enhancing effect on 
the survival and proliferation of early stem cells (Petzer et al. 1996b, Kobari et al. 
1998, Luens et al 1998), suppressing apoptosis of CD34+ cells and recruiting 
primitive cells into rapid division (Murray et al 1999). The combination of these 
cytokines with either G-CSF or IL-6 or both was further evaluated in this study. The 
addition of G-CSF appeared to enhance the expansion of some cell compartments but 
inhibit others. G-CSF increased the expansion of total nucleated cells and likely 
enhanced the maturation to some extent. The effects of this cytokine were mostly 
favorable in QBSF-60 and X-Vivo 10. Lefebvre et al. (2000) confirmed that G-CSF 
did not improve MK production, but rather favored the myeloid lineages. Kobari et 
a/. (2000) cultured CB CD34+ cells in serum-free IMDM supplemented with the 
same cytokine combination, TSFG with slightly different cytokine concentrations 
(100 ng/ml TPO, 100 ng/ml SCF, 100 ng/ml FL and 10 ng/ml G-CSF) expanded total 
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nucleated cells, CD34+ cells, CFU-GM and BFU-E after 14 days of culture to 1,613-， 
119-, 278- and 50-fold, respectively. In our conditions TSFG, expansions of total 
nucleated cells, CD34+ cells, CFU-GM and BFU-E were 1,680-, 196-, 741- and 478-
fold, respectively after 12 days of culture, again showing that serum-free medium 
might be superior to traditionally used IMDM. They also found that expanded cells 
were able to engraft in NOD/SCID mice and differentiate into myeloid, erythroid and 
lymphoid cells. Considering that G-CSF has been applied extensively for clinical use 
(Stahel et al. 1994, Klumpp et al. 1995, Lane et al 1995, Li et al 1999), its inclusion 
in the cytokine cocktail should be considered. 
The addition of IL-6 produced favorable expansion outcomes including SCID-
repopulating cells as reported in other studies (Sui et al 1999, Kusadasi et al. 2000, 
Ueda et al 2000). Kusadasi et al (2000) compared different combinations containing 
the four cytokines, TPO, SCF, FL and IL-6. The expansion of both early and late 
progenitors was most efficient using all the four cytokines. Expanded cells were 
shown to be able to engraft in NOD/SCID mice (Kusadasi et al 2000, Ueda et al 
2000). Ueda et al. (2000) reported that a substantial increase of human CD45+ cells 
engrafted in NOD/SCID mice was observed when IL-6 was added to the cultures 
with TPO, SCF and FL. Up until now, IL-6 has not been widely used for patient 
treatments (Schrezenmeier et al 1995, Bracho et al 2001) or clinical ex vivo 
expansion (Bertolini et al. 1997b). Further evaluation and development IL-6 for the 
expansion of hematopoietic stem and progenitor cells might be desirable. 
Recent studies have assessed the use of high dosage (100 ng/ml) of TPO and SCF for 
the ex vivo expansion of stem and progenitor cells for clinical applications (McNiece 
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et al 1999，Reiffers et al 1999, Paquette et al 2000, McNiece et al 2001). The 
effects of two dosage (50 ng/ml and 100 ng/ml) of TPO and SCF were investigated 
in the presence of QBSF-60 serum-free medium. The high dose TPO and SCF 
increased the expansion of all cell compartments without the exhaustion of early 
progenitors, showing that high dosage of TPO and SCF might be applied in the 
clinical expansion protocols. 
In Chapter Four, we demonstrated that FL supported the expansion of both early and 
megakaryocytic progenitors in serum-containing IMDM. In this chapter, we further 
investigated the effects of FL in the serum-free QBSF-60 medium. The expansion of 
total nucleated cells, CD34+ cells, CD34+CD38- cells and all lineages of CFU were 
enhanced with the addition of FL. In accordance with previous studies, FL increased 
CFU-MK and the percentage of CD61+CD41+ cells in QBSF-60, showing that FL 
had some positive effects on megakaryocytic progenitors in the present culture 
system. Comparing the effects of FL on the engraftment of expanded cells into 
NOD/SCID mice, expanded cells with FL showed a trend of higher percentages of 
human CD45+ cells and CD61+ cells in the BM of mice. However, the results were 
not statistically significant possibly due to the small sample size. Further experiments 
might be required to confirm this finding. 
In conclusion, QBSF-60 or to a lesser extent, StemSpan supported the expansion of 
early stem and progenitor cells as well as committed myeloid and erythroid 
progenitors while X-Vivo 10 supported the most efficient expansion of 
megakaryocytic progenitors. In addition, expanded cells cultured with the cytokine 
combinations TSG and TSFG in QBSF-60 successfully engrafted in NOD/SCID 
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mice and differentiated into functional cells of myeloid and lymphoid lineages. We 
also demonstrated a higher dose of TPO and SCF, and the presence of FL enhanced 
the expansion whereas autologous CB plasma reduced the yields of CD34+ cells and 
CFU-GEMM. These culture systems might be applicable to clinical expansion in the 
attempt to reduce the severity of cytopenia. 
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Figure 6.1 Fold Increase of Total Nucleated Cells at Day 8 and Day 12 
Enriched CD34+ cells from at 2 x lO'^ /ml were cultured in four media 
- I M D M + 10% FCS, X-Vivo 10, QBSF-60 and StemSpan, with four 
cytokine combinations (T — 50 ng/ml TPO, S - 50 ng/ml SCF, F — 80 
ng/ml FL, G — 40 ng/ml G-CSF and 6—100 ng/ml IL-6) for 12 days. 
Results were presented as mean 士 S.E. TNC — total nucleated cells, n 
=10, *p <0.05 
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Table 6.1 Expansion of CD34+ Cells and CD34 CD38 Cells at Day 8 and 
Day 12 
Enriched CD34+ cells at 2 x lOVml were expanded in IMDM + 10% 
FCS, X-Vivo 10, QBSF-60 or StemSpan in the presence of four 
cytokine combinations. CD34+ cells and CD34^CD38" cells were 
analyzed by flow cytometry after expansion. The resulting 
populations were expressed as mean 士 S.E. derived from 1 ml of 
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Figure 6.2 Fold Increase of CD34+ Cells at Day 8 and Day 12 
The yields of CD34+ cells after expansion were analyzed by flow 
cytometry. An increase in the fold increase of CD34+ cells was seen at 
day 12 of culture, except for the cytokine combination TSFG6. Fold 
increases of CD34+ cells at day 12 were less than those at day 8 in 
IMDM, X-Vivo 10 and StemSpan with TSFG6. n = 10, * p < 0.05 
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Figure 6.3 Fold Increase of CD34+CD38- Cells at Day 8 and Day 12 
CD34+CD38- cells after expansion were analyzed by flow cytometry. 
An increase in fold increase of CD34+CD38- cells was seen at day 12 
of culture, except for the cytokine combination TSFG6. n = 10, * p < 
0.05 
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Table 6.2 Fold Increase of Different Lineages of Colony-Forming Units at 
Day 8 and Day 12 
Enriched CD34+ cells at 2 x lOVml were expanded in IMDM + 10% 
FCS, X-Vivo 10，QBSF-60 or StemSpan in the presence of four 
cytokine combinations. Fold increases of CFU production were higher 
at day 12 than those at day 8. Results were expressed as mean 土 S.E. n 
=10, * p <0.05 
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Figure 6.4 Expansion of CD61+CD41+ Cells at Day 8 and Day 12 
Megakaryocytic CD61+CD41+ cells after expansion were analyzed by 
flow cytometry. The yields of CD61+CD41+ cells were significantly 
higher at day 12 than those at day 8 in the presence of cytokine 
combinations TSF, TSFG and TSF6 in IMDM, X-Vivo 10, QBSF-60 
and StemSpan. n = 10, * p < 0.05 
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Figure 6.5 Fold Increase of CFU-MK at Day 8 and Day 12 
Expanded cells at 3 x lOVml were seeded in the plasma clot system 
for CFU-MK assay. The fold increases of CFU-MK at day 12 were 
significantly higher when compared to those at day 8. n 二 10, * p < 
0.05 
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Figure 6.6 Immunofluoresence Staining of CFU-MK 
Expanded cells were harvested for CFU-MK assay using the plasma 
clot system. After 12 days of incubation, colonies were stained with 
CD61-FITC. Three or more CD61-positive cells were scored as a 
CFU-MK colony. Photograph was taken at 50x original 
magnification. 
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Table 6.3 Effects of Various Media and Cytokine Combinations on the Ex 
Vivo Expansion of Cord Blood CD34+ Cells 
Enriched CD34+ cells at 2 x lOVml were expanded in the presence of 
four cytokine combinations in four media for 12 days. The resulting 
populations derived from 1 ml of culture at day 0 were expressed as 
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Figure 6.7 Effects of Culture Media on the Fold Increase of Total Nucleated 
Cells 
Enriched CD34+ cells at 2 x lOVml were cultured in four media 一 
IMDM + 10%FCS, X-Vivo 10, QBSF-60 and StemSpan in the 
presence of four cytokine combinations. After 12 days of culture, 
StemSpan supported significantly higher expansion of total nucleated 
cells (TNC) than IMDM + 10% FCS, X-Vivo 10 and QBSF-60. n = 
10, * p < 0.05 (StemSpan vs other media) 
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Figure 6.8 Effects of Culture Media on the Fold Increase of CD34+ Cells and 
CD34 CD38 Cells 
Expanded cells were harvested for flow cytometry analysis of CD34+ 
cells and CD34^CD38" cells. The fold increases of both CD34+ and 
CD34^CD38" cells were the highest when cells were cultured in 
QBSF-60. n = 10, * p < 0.05 (QBSF-60 vs other media) 
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Figure 6.9 Effects of Culture Media on the Fold Increase of CFU 
The colony-forming capacity of expanded cells to different lineages of 
hematopoietic cells was assayed using methylcellulose system. * and 甘 
represented significant differences were observed in the fold increases 
of CFU in QBSF-60 and StemSpan, respectively when compared to 
those in that particular medium. + represented both QBSF-60 and 
StemSpan supported significantly higher fold increases of CFU (p < 
0.05). n = 10 
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Figure 6.10 Effects of Culture Media on CD61+CD41+ Cells and CFU-MK 
The percentages of CD61+41+ cells were analyzed by flow cytometry. 
CFU-MK was assayed using the plasma clot system. Results 
demonstrated that the highest percentages of CD61+41+ cells and fold 
increase of CFU-MK were observed in cultures with X-Vivo 10 (* p < 
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Figure 6.11 Effects of Autologous Cord Blood Plasma on the Fold Increase of 
CD34+ Cells 
CD34+ cells were analyzed by flow cytometry after 12 days of 
expansion. No significant difference in the fold increase of CD34+ cell 
was observed when FCS was replaced by autologous plasma in 
IMDM cultures. In cultures with X-Vivo 10, QBSF-60 and StemSpan, 
the addition of autologous plasma significantly reduced the fold 
increases of CD34+ cells, n = 6, * p < 0.05 
147 
_ 300 T pasma~j ^^ ^ X-Vivo 10 
$ • + plasma i 
I 2 5 0 十 I 2 5 0 T 
o w. • 
尝 200 : c 200 T 工 * r^ 
o 2 rn 
it. 150 ： £ 150 -
<2 J * 
g 100 I = 100 - * rh 
. o n 
S 50 十 宾 50 --
0 I r - 1 , r m , r m , r m 丨 S p L , I ^ , I L I L 
g TSF TSFG TSF6 TSFG6 g TSF TSFG TSF6 TSFG6 
“ O 
300 StemSpan 
它 州 u T 一 300 丁 lA T T i ® 
ra ocn I * * w 
g 250 T 丁 T * h S 250 -
尝 200 丄 pL^ 门 差 200 — T * r^ * i * 
o 2 rh 
1 1 5 � 门 
s 1 0 0 卜 云 1 0 0 十 . o 
S 50 t I 50 I 
V 0 • i • I Mh + 二 0 , I L I a I • I L 
8 TSF TSFG TSF6 TSFG6 g TSF TSFG TSF6 TSFG6 
^ o 
Figure 6.12 Effects of Autologous Cord Blood Plasma on the Fold Increase of 
CD34+CD38 Cells 
After 12 days of expansion, cells were harvested for analysis of 
CD34+CD38- cells by flow cytometry. In IMDM cultures, the effect of 
autologous plasma on the expansion of CD34^CD38' cells was similar 
to that of FCS. However, the addition of autologous plasma to the 
serum-free media, X-Vivo 10 and QBSF-60 and StemSpan, 
significantly decreased the fold increases of CD34^CD38" cells, n = 6, 
*p<0 .05 
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Table 6.5 Effects of Autologous Cord Blood Plasma on the Fold Increase of 
Different Lineages of Colony-Forming Units 
Enriched CD34+ cells at 2 x 10^/ml were expanded in IMDM, X-Vivo 
10, QBSF-60 and StemSpan in the presence or absence of autologous 
CB plasma for 12 days. (-) represented the absence of autologous CB 
plasma, while (+) meant 10% autologous plasma was added. Results 
were expressed as mean 土 S.E. n = 6, * p < 0.05 
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Figure 6.13 Effects of Autologous Cord Blood Plasma on the Expansion of 
CD61+CD41+ Cells 
The yields of CD61+CD41+ cells were analyzed by flow cytometry 
after 12 days of culture in four media with or without 10% autologous 
plasma. Significant decreases in the yields of CD61+CD41+ cells were 
observed in cultures in which autologous plasma was present, n = 6, * 
p<0.05 
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Figure 6.14 Effects of Autologous Cord Blood Plasma on the Fold Increase of 
CFU-MK 
Expanded cells at 3 x 10^/ml were seeded in the plasma clot system 
for CFU-MK assay. Similar to the expansion of CD61+CD41+ cells, 
the addition of autologous plasma led to significant decreases of fold 
increases of CFU-MK in the majority of cultures, n = 6, * p < 0.05 
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Figure 6.15 Effects of Granulocyte-Colony Stimulating Factor and 
Interleukin-6 on the Fold Increase of Total Nucleated Cells 
Enriched CD34+ cells at 2 x lO'^ /ml were cultured for 12 days in four 
media with four cytokine combinations. The addition of * G-CSF and 
IL-6 to the cultures increased total nucleated cells when compared to 
the respective treatments without that cytokines (p < 0.05). n = 10 
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Figure 6.16 Effects of Granulocyte-Colony Stimulating Factor and 
Interleukin-6 on the Fold Increase of CD34+ Cells and 
CD34+CD38 Cells 
CD34+ cells and CD34"^CD38' cells were analyzed by flow cytometry. 
Significant differences were observed when * G-CSF or 并 IL-6 was 
added (p < 0.05). n = 10 
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Figure 6.17 Effects of Granulocyte-Colony Stimulating Factor and 
Interleukin-6 on the Fold Increase of CFU 
The fold increases of total CFU (CFU-GM, BFU/CFU-E, CFU-
GEMM), CFU-GM, BFU/CFU-E and CFU-GEMM were examined. * 
(with G-CSF vs without G-CSF) and # (with IL-6 vs without IL-6) p < 
0.05, n = 10 
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Figure 6.18 Effects of Granulocyte-Colony Stimulating Factor and 
Interleukin-6 on the Expansion of CD61+CD41+ Cells and CFU-
MK 
The expansion of CD61+CD41+ cells and CFU-MK were analyzed. 
The percentage of CD61+CD41+ cells declined and the fold increase 
of CFU-MK elevated when G-CSF was added to the cultures (* p < 
0.05). The addition of IL-6 increased the fold increase of CFU-MK (# 
p<0.05). n = 10 
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Table 6.6 Effects of Flt-3 Ligand and Increased Dosage of Thrombopoietin 
and Stem Cell Factor on the Ex Vivo Expansion of Cord Blood 
CD34+ Cells 
— TSG50 TSFG50 TSGIOO TSFGIOO 
Total Nucleated Cells ( x l O ^ ) 7 . 3 2 ± 0 . 5 5 ' 1 2 . 7 ±0.91**' 7.65 ± 0 .74 '13.2+1.04** ' 
CD34+Cells (o/o) 3.09±0.49# 7.03±1.11**# 3.36±0.55# 8.25±1.23**# 
CD34+Cells (xl05) 2.19±0.34*# 8.59±1.53**# 2.88±0.51*# 10.4±1.36**# 
CD34+CD38-Cells (o/o) 1.32±0.33# 2.09±0.48**# 1.72±0.43# 3.12±0.73**# 
CD34^CD38' Cells (xlO^) 0.96±0.27*# 2.52±0.65**# 1.41 ±0.36*" 3.85 士 0.87**# 
Total CFU (xlO^) 2.65±0.37**# 4.06±0.36# 3.12±0.39**# 4.42 ± 0.47# 
CFU-GM (xlO^) 1.94±0.26**# 2.98 ± 0.26# 2.29 ± 0.27**# 3.24±0.33# 
BFU/CFU-E (xl04) 6.29±0.97**# 9.57 土 0.97**# 10.5±1.29**# 7.42±1.05**# 
CFU-GEMM (xlO^) 2.88±0.36**# 4.51±0.47# 3.42±0.42**# 4.93 ± 0.60# 
CD61+CD41+Cells (o/o) 12.7±1.37**# 8.4±1.16# 15.6±1.34**# 8.68±1.41# 
CD61+CD41+Cells (xl05) 9.35 ±1.29** 10.3 ±1.62 13.0 土 1.88** 11.0 ±1.66 
CFU-MK (xl05) 1.06±0.21**# 1.65±0.32**# 1.27±0.24**# 2.76 ±0.38氺 
Enriched CD34+ cells at 2 xloVml were cultured for 12 days in QBSF-60 with four 
cytokine combinations - (1) TSG: 50 ng/ml TPO, 50 ng/ml SCF and 40 ng/ml G-
CSF; (2) TSFG: 50 ng/ml TPO, 50 ng/ml SCF, 80 ng/ml FL and 40 ng/ml G-CSF; 
(3) TSGIOO: 100 ng/ml TPO, 100 ng/ml SCF and 40 ng/ml G-CSF; (4) TSFGIOO: 
100 ng/ml TPO, 100 ng/ml SCF, 80 ng/ml FL and 40 ng/ml G-CSF. Results were 
expressed as mean 士 S.E. n = 8，* p < 0.05 and ** p < 0.01 (TSG50 vs TSGIOO or 
TSFG50 vs TSFGIOO), # p < 0.01 (TSG vs TSFG or TSGIOO vs TSFGIOO). 
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Figure 6.19 Effects of Flt-3 Ligand and Increased Dosage of Thrombopoietin 
and Stem Cell Factor on the Fold Increase of Total Nucleated 
Cells, CD34+ Cells and CD34 CD38 Cells 
Total nucleated cells (TNC), CD34+ cells and CD34^CD38" cells were 
analyzed after 12 days of culture. Increased dosage of TPO and SCF 
led to higher fold increases of TNC, CD34+ cells and CD34+CD38— 
cells (* p < 0.05). The addition of FL also enhanced the expansion of 
these cell compartments significantly (# p < 0.05 and + p < 0.01). n = 8 
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Figure 6.20 Effects of Flt-3 Ligand and Increased Dosage of Thrombopoietin 
and Stem Cell Factor on the Fold Increase of Different Lineages 
of CFU 
Expanded cells were harvested and assayed for the colony-forming 
capacity. Increased dosage of TPO and SCF resulted in significant 
differences on the expansion of CFU (* p < 0.05). Significant 
differences were also observed when FL was added to the cultures (# p 
<0.01). n = 8 
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Figure 6.21 Effects of Flt-3 Ligand and Increased Dosage of Thrombopoietin 
and Stem Cell Factor on the Fold Increase of CFU-MK 
Expanded cells were harvested for CFU-MK assay. The addition of 
FL and increased dosage of TPO and SCF enhanced the expansion of 
CFU-MK. n = 8，* p < 0.05 when comparing 50 ng/ml TPO and SCF 
with 100 ng/ml TPO and SCF. # p < 0.01 when investigating the 
effects of FL. 
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Figure 6.22 Engraftment of Expanded Human Cells in NOD/SCID Mice 
Enriched CD34+ cells expanded in QBSF-60 for 12 days with 50 
ng/ml TPO, 50 ng/ml SCF and 40 ng/ml G-CSF 士 80 ng/ml FL, were 
infused into irradiated NOD/SCID mice. After 6 weeks, the 
engraftment of human CD45+ cells in the bone marrow (BM), spleen 
(Sp) and peripheral blood (PB) were quantified by flow cytometry. 
Results were expressed as the percentage of viable cells, n = 13 for 
TSG and n - 12 for TSFG. 
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Figure 6.23 Subsets of Human Hematopoietic Cells in the Bone Marrow of 
Engrafted NOD/SCID Mice 
The engraftment of human stem and progenitor (CD34+)，myeloid 
(CD33+, CD 14+), lymphoid (CD 19+) and megakaryocytic (CD61+) 
cells were detected in the BM of transplanted NOD/SCID mice after 6 
weeks of transplantation. Results were expressed as the percentage of 
human CD45+ cells. 
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CHAPTER SEVEN 
GENERAL DISCUSSION AND CONCLUSION 
The ex vivo expansion of CB stem and progenitor cells has been suggested as a 
strategy of overcoming the insufficient cell dose in a collection. If successful, the 
expanded cell population might reduce the morbidity, mortality and cost associated 
with posttransplant neutropenia and thrombocytopenia. In addition, the expanded CB 
might be suitable for transplanting patients of large body weight. Limited clinical 
trials have been performed using ex vivo expanded CB for transplantation and the 
outcomes of these studies were inconsistent. At present, no standard protocol has 
been recommended for the ex vivo expansion of CB stem cells. 
The aims of this project were to optimize the culture conditions for the ex vivo 
expansion of enriched CB CD34+ cells by investigating the effects of cytokines, 
culture durations, media, serum supplements and a novel MBL on the system. The 
read-out assays included CD34+, CD34^CD38", CD61+CD41+ cells, CFU of the GM, 
E and MK lineages and SRC. 
Comparing the effects of two early-acting cytokines FL and SCF on the expansion of 
the megakaryocytic progenitor cells in the presence of TPO, IL-3 and IL-6, we 
demonstrated that FL supported more efficient expansion of CD34+ cells and CFU-
MK up to 23.8- and 584-fold, respectively. FL receptors were undetectable in 
megakaryocytic cell lines, suggesting that FL might exert its effects at the stage of 
stem and progenitor cells. In QBSF-60 serum-free medium and cytokines TPO, SCF 
and G-CSF, the addition of FL again improved the expansion outcomes of all cell 
types studied. In this system, the SRC in the spleen were significantly higher in the 
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NOD/SCID mice infused with FL-expanded cells although only a trend was observed 
in the BM of these animals. 
Our preclinical study demonstrated that QBSF-60 supported the highest yields of 
early progenitors CD34+ cells, CD34^CD38" cells and CFU-GEMM among four 
media compared. Interestingly, X-Vivo 10 enhanced the highest expansion of 
megakaryocytic progenitors, CD61+CD41+ cells and CFU-MK. In addition, the 
culture duration of 12 days with 100 ng/ml TPO, 100 ng/ml SCF, 80 ng/ml FL and 
40 ng/ml G-CSF in the absence of autologous plasma appeared to be the optimal 
condition for the expansion� 
It is of great concern that the pluripotent stem cells might be exhausted during ex 
vivo expansion and for this reason, most clinical trials were performed with the 
infusion of expanded cells together with unmanipulated cells. In this study, we 
investigated the effect of a novel MBL on the preservation of early stem cells and 
demonstrated that MBL at 200 ng/ml significantly preserved CFU-GEMM for 35 
days without serum or cytokine supplements. MBL also enhanced the ex vivo 
expansion of CD34^CD38" cells and CFU-GEMM in the presence of TPO, SCF and 
FL. However, the SRC were not expanded, possibly because of the sensitivity of the 
model. Future studies will be focused on a modified animal model such as the 
N0D/SCID-P2m-z- mice, which might be able to distinguish the subtle differences 
between long-term and short-term SRC. 
For future studies, we are pursuing to establish the optimized system for the clinical-
scale expansion of CB CD34+ cells. We anticipated that similar conditions could be 
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applied for the expansion of BM and mobilized PBSC. Considering the preferential 
conditions for the expansion of early/myeloid progenitor cells and the 
megakaryocytic progenitor cells in terms of culture media and cytokine 
requirements, we strongly suggested that these two classes of progenitor cells be 
expanded in separate culture systems. 
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